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ABSTRACT 
Prescription opioid use and misuse poses a significant public health challenge to the 
United States. In this dissertation we use the three-manuscript format to address some 
the areas of unmet research. Each manuscript has an abstract, introduction, 
background, methods, results, discussion, and conclusions sections.  
Manuscript 1: We used a retrospective cohort design to examine the association 
between the patterns of initial prescription opioid use for non-cancer pain and risk of 
all-cause mortality among an insured opioid-naïve patient population in the U.S.  
Multivariable Cox regression model was used to estimate the association of initial 
pattern of opioid use with all-cause mortality, adjusting for baseline covariates to 
control for confounding.  We found that incident chronic opioid use was associated 
with an increased risk of all-cause mortality that persisted for up to 5 years after the 
initiation of opioid therapy.  
Manuscript 2: We used a cross-sectional study of the Rhode Island Prescription Drug 
Monitoring Program data to estimate the annual statewide spending for prescription 
opioids in Rhode Island. A generalized linear model with gamma distribution with a 
log link function was used to estimate the relative differences in per-patient annual 
adjusted average opioid prescription cost. We found that in 2015 the annual 
expenditure for opioid prescriptions in Rhode Island was $44,271,827. Commercial 
insurance bore the majority of the cost of prescription opioid use, but cost per patient 
was highest among Medicare beneficiaries. 
Manuscript 3: Using the 2015 Prescription Drug Monitoring Programs data for 
Rhode Island we examined the association between potential prescription opioid 
 
 
misuse and method of prescription opioid payment used. A multivariable log-binomial 
regression model was used to examine the risk of potential opioid misuse, controlling 
for sex, age group, type of opioid used, and concurrent benzodiazepine use. We found 
that patients on chronic opioid therapy who pay for some, but not all, opioid 
prescriptions in cash could be associated with potential opioid misuse only when the 
patient has other health insurance coverage. 
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PREFACE 
This dissertation is written in the manuscript format, and is comprised of three 
manuscripts dealing with different aspects of the current prescription opioid epidemic 
facing the United States: risk of all-cause mortality, cost burden, and the risk of 
potential opioid misuse.   
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ABSTRACT 
Background: Patients with no prior exposure to opioids are often prescribed opioid 
analgesics for acute pain in the emergency room or office setting. Initial opioid 
prescription intended for short term use may result in chronic opioid use among 
opioid-naïve patients, increasing the risk of opioid overdose and death.  
Objective: To examine the association between the patterns of initial prescription 
opioid use for non-cancer pain and risk of all-cause mortality among an insured 
opioid-naïve patient population in the U.S.  
Methods: This retrospective cohort study used de-identified administrative claims 
database (Optum Clinformatics® Data Mart; OptumInsight, Eden Prairie, MN). 
Opioid prescriptions filled between January 1, 2010 and December 31, 2015 by 
opioid-naïve patients (in last 6 months) aged 18 years and above with no history of 
opioid use disorder, and not receiving cancer or palliative care were identified. All 
patients were required to have continuous medical and prescription coverage 6 months 
before and after the first opioid prescription. Based on initial pattern of opioid use (6 
months after first prescription), patients were categorized either as incident daily 
(chronic) opioid users if they had more than 90 days’ supply of opioids, or as non-
daily users. Follow-up time was measured from 6 months after the index date to the 
end of eligibility or death, which ever came first. Multivariable Cox regression model 
was used to estimate the association of initial pattern of opioid use with all-cause 
mortality, adjusting for baseline covariates to control for confounding.  
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Results: A total of 4,005,001  patients were included in the study, of which 2.7% were 
incident daily opioid users; 54.8% were female; median age was 50 years; mean 
Charlson comorbidity index was 0.0 (standard deviation [sd] = 0.78); and mean daily 
morphine milligram equivalent (MME) was 34.10 (95% CI: 34.08 - 34.12). Among 
incident daily opioid users, 50% of patients were aged 65 and older and 55% had 
Medicare. Patients were followed for up to 6 years (median of 2.5 years) with a total 
of 11,294,819 person-years during which 39,417 (1%) died. Overall crude death rate 
was 349 deaths per 100,000 person-years; and there were 1,159 more deaths per 
100,000 person-years among incident daily users than non-daily users. After adjusting 
for baseline covariates, patients who were incident daily users had more than twice the 
risk of all-cause mortality compared to non-daily users (hazard ratio [HR] = 2.57; 95% 
CI: 2.40 - 2.75). The hazard of death was slightly attenuated over time (HR at 5 years 
= 1.86; 95% CI: 1.72 - 2.02).  
Conclusion: Almost 3% of opioid-naïve patients became chronic opioid users within 
the first 6 months of initial therapy. Incident chronic opioid use was associated with an 
increased risk of all-cause mortality that persisted for up to 5 years after the initiation 
of opioid therapy. Our findings are consistent with current Center for Disease Control 
and Prevention recommendation to use the lowest effective prescription opioid dose 
for the shortest duration among opioid-naïve patients. 
INTRODUCTION 
Pain is one of the most common reasons for an emergency department or outpatient 
office visit.1-4 Opioid analgesics are often prescribed for acute pain in these settings 
because there is an established role of prescription opioid therapy in the management 
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of moderate to severe acute pain and cancer pain.5 However, the use of prescription 
opioids for chronic non-cancer remains controversial.6-11 That notwithstanding, each 
year about 20% of adults in the United States are prescribed opioid analgesics for a 
variety of painful conditions ranging from acute injury to chronic non-cancer pain and 
terminal comfort measures, in part, because adequate and rapid pain relief has been 
used as a metric for patient satisfaction ratings.12,13 Initial opioid therapy often 
intended by prescribers for short-term use often leads to unintended long-term use 
with adverse health outcomes including opioid misuse, opioid use disorder (OUD), 
overdose, and opioid-related deaths.14-18 In recent years, deaths from drug overdose 
have increased dramatically, exceeding the number of deaths from motor vehicle 
accidents, to become the leading cause of accidental death in the United States.19-22 
The role of the initial pattern of opioid use in premature death is largely unknown.  
BACKGROUND 
Since 2013, mortality rates from drug overdose in the United States have frequently 
exceeded those from motor vehicle accidents and homicide. In 2015, drug overdose 
was responsible for over 50,000 deaths in the United States, with almost 63% related 
to opioid use - representing an age-adjusted opioid-involved death rate of 10.4 per 
100,000 people.23 More than 60% of all opioids involved in drug overdose deaths are 
prescribed by healthcare providers.20,24,25 The number of deaths attributed to 
prescription opioid has now exceeded the total number of deaths from suicide and 
motor vehicle accidents combined.26 Over the past decade, the rate of opioid-related 
overdose death has increased by about 200%.23 Certain groups of opioid users are 
particularly vulnerable to opioid overdose, including those who seek care from 
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multiple providers to obtain the same prescription opioid analgesic27,28, those on high 
daily dosages of opioids28-32, those with a history of mental illness33, and Medicaid 
beneficiaries.33,34 Prior studies have also established the use of long-acting opioids, 
especially at higher doses ( ≥ 50 morphine milligram equivalent [MME] per day) for 
chronic pain, use of ≥4 prescribers or pharmacies per year, and concurrent use of 
psychoactive medications including benzodiazepines and gabapentin as significant 
risk factors for opioid-related overdose death.21,32,35-40 Several studies have found 
concurrent benzodiazepine use in 30% to 60% of opioid-related deaths.41-43 In 
accordance with changes in recent opioid prescribing guidelines, the Food and Drug 
Administration has issued a boxed warning limiting the concurrent use of 
benzodiazepines with opioids.11,44,45 Another study of opioid-naïve patients who had 
low-risk surgery found that the use of prescription opioids within 7 days of surgery 
was associated with an increased risk of long term opioid use.46 Other populations at 
greater risk of harm include patients with sleep disorders, renal and liver failure, older 
adults, patients with mental health conditions, and patients with alcohol or other 
substance use disorders.47-50 
The pattern of prescription opioid use varies from one individual patient to 
another depending on the indication, comorbidity, and local opioid prescribing norms. 
Some patients require opioid medications on a regular basis; some require it as-
needed, and others take it both regularly and as needed. A recent case-control study 
used the Veteran Health Administration data to examine the relationship between the 
patterns of opioid use and health outcomes found that receiving as-needed and 
regularly scheduled opioid therapy was not associated with increased risk of 
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overdose.32 Little attention has been given to the effects of the initial pattern of 
incident opioid use on the risk of death from all causes among patients receiving 
opioid therapy for non-cancer, non-terminal care. Current guidelines for opioid use 
address risks associated with chronic opioid therapy, which represents only about 5% 
of episodes of opioid use each year in the United States and the remaining patients 
take prescription opioids somewhat irregularly and the risk associated with this pattern 
of use warrants further investigation.51 Understanding the risk of mortality associated 
with the incident chronic opioid use is an important step towards decreasing opioid-
related mortality. To address this gap in the evidence base, we examined the 
relationship between initial patterns of incident opioid use on the five-year mortality 
rate among opioid users without a cancer diagnosis.  
METHODS 
Study design and data source: This was a retrospective cohort study using de-
identified administrative claims database (Optum Clinformatics® Data Mart; 
OptumInsight, Eden Prairie, MN). The database includes claims on health care 
utilization of about 35 million unique patients of all ages from geographically diverse 
regions of the United States who are privately insured or Medicare Advantage 
beneficiaries. The database provides information on member demographics and 
eligibility history, inpatient and outpatient medical services, outpatient pharmacy 
claims, and some laboratory results from January 1, 2010 to December 31, 2015. 
Clinical procedures and professional services are recorded using the Current 
Procedural Terminology (CPT) codes while associated diagnoses are recorded using 
the International Classification of Diseases, 9th and 10th Revisions, Clinical 
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Modification (ICD-9 and ICD-10) codes. Only enrollees with both a medical and 
prescription drug coverage are included in the database. To improve data quality and 
accuracy, claims submitted for payment by facilities, providers and pharmacies are 
usually verified, adjudicated, and adjusted prior to inclusion in the database. The 
dataset is linked to an existing Social Security Administration dataset which contains 
mortality information for all enrollees. The study protocol was approved by the 
University of Rhode Island Institutional Review Board. 
Study population: All patients in the database who filled at least one opioid 
prescription were eligible for the study. Therapeutic class codes were used to identify 
all opioid prescriptions filled between January 1, 2010 and December 31, 2015 (Figure 
1). Prescriptions with improbable or missing quantity or days’ supply, and bulk 
containing agents were excluded. We focused on opioid prescription fills among 
opioid-naïve patients, defined as having no opioid prescription or OUD claim in the 
first observed 6 months of enrolment in the database.52 The index date was defined as 
the date of the first opioid prescription among opioid-naïve patients (Figure 2). To 
allow for adequate ascertainment of baseline characteristics and initial pattern of 
prescription opioid use, we required patients to be continuously enrolled for at least 6 
months before (i.e., pre-index baseline period) and 6 months after the index date (i.e., 
index period). Patients were excluded if they were younger than 18 years old as of the 
index date, or if their first opioid prescription was for a medication used to treat OUD, 
implying prior exposure to opioids was likely.53 The study sample was further 
restricted to patients with no claims for any cancer diagnosis, or indication of 
palliative or hospice care. All patients were required to have a confirmed cancer 
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diagnosis was defined as having at least two separate medical claims with a cancer 
diagnosis, with service dates at least 30 days apart. The cancer diagnosis codes could 
be in either a primary or secondary position in an inpatient or outpatient claim.54 
Hospice and palliative care were identified with ICD-9 and CPT codes. The final 
study sample consisted of 4,005,001 patients. 
Exposure definition: The index period (6 months following the first opioid 
prescription claim), was used to ascertain the initial pattern of prescription opioid use. 
Based on the Consortium to Study Opioid use and Trends criteria,38,55  patients were 
categorized either as daily (chronic) prescription opioid users if they had more than 90 
non-overlapping days’ supply of prescription opioids during the index period or as 
non-daily users otherwise. We computed the average daily morphine milligram 
equivalents (MME), and the number of providers and pharmacies used during the 
index period to fulfil opioid prescription requirements. Opioid prescription dosing 
information was converted to daily MME by multiplying the quantity of each 
prescription by the strength of the prescription, and multiplying this total by 
conversion factors published by the Center for Disease Control and Prevention 
(CDC).56 For patients who received more than one opioid prescription on any given 
day, the MME of all prescriptions were added together. Based on recent CDC 
treatment guidelines, the average daily MME was categorized as < 50, 50-90, or >90 
MME daily.11 
Covariate information: The dataset contains information on gender (male or female), 
type of insurance (commercial or Medicare), type of health plan, and US states that 
were grouped into five census regions. Age in years was calculated as of the index 
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opioid prescription date. Clinical characteristics that may influence the initial pattern 
of prescription opioid use and/or time to mortality, such as Charlson comorbidity 
index (a common measure of overall medical comorbidity), common pain conditions, 
mental health disorders, surgical procedures, pregnancy, occurrence of sprains and 
fractures, and substance use disorders such as alcohol, smoking, and OUD were 
recorded during the baseline/index period using ICD-9 and ICD-10 codes.57,58 All 
clinical diagnoses were used to indicate if the patient had been diagnosed with or 
treated for the condition during the baseline/index period. Use of psychiatric 
medications such as benzodiazepines, antidepressants, antipsychotics, and gabapentin 
was defined as having one or more prescription claims during the index period, 
irrespective of whether that use overlapped with use of an opioid prescription.38 A 
listing of ICD-9, ICD-10 and CPT codes used to identify various conditions is 
provided in Appendix A. 
Outcome measurement: All-cause mortality was ascertained using mortality 
information from Social Security Administrations Death Index file which provided the 
month and year of death without information on the underlying cause of death. The 
date of death was imputed to be the last calendar day of each month. Observation time 
was measured from 6 months after the index date (i.e., the end of the index period) to 
the end of eligibility, or death, which ever came first. If the patient was not seen for 
one entire calendar year, their follow-up time was censored at the end of that calendar 
year. All patients were administratively censored at the end of the study (i.e., 
December 31, 2015). 
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Statistical Analysis: Descriptive statistics were computed for demographic, clinical, 
and prescription characteristics at baseline and presented by initial pattern of 
prescription opioid use. We computed overall median follow-up time and crude death 
rate for the study sample. Overall survival among the two the groups defined by initial 
patterns of incident opioid use (daily versus non-daily prescription opioid users) was 
compared using unadjusted and inverse-probability-weighted Kaplan-Meier survival 
curves.59,60 We fit unadjusted and adjusted multivariable Cox regression model to 
estimate the hazard ratios (HR) with 95% confidence intervals (CI) that were used to 
determine the association of initial patterns of opioid use on the rate of all-cause 
mortality, adjusting for patient-level baseline covariates to control for confounding. 
Restricted quadratic splines were used to control finely and more flexibly for 
continuous confounders (age and average MME) allowing for a non-linear relationship 
with time-to-death.61 Based on a statistical test and graphical visual inspection, the 
assumption of proportional hazards for initial pattern of prescription opioid use 
(primary exposure) was not satisfied (ρ = 11,777; 𝜒2=156, degree of freedom [df]=1, 
p-value < 0.0001), so a cross-product term between the logarithm of time (in months) 
and baseline exposure was included in the model. All data manipulations and 
statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC) 
and R statistical software, version 3.2.3 (R Core Team 2016). All tests of statistical 
significance were two-sided and performed at the 0.05 significance level.  
RESULTS 
A total of 4,005,001 patients were included in the study, of which 2.7% were daily 
opioid users; 54.8% were female; median age was 50 years; mean Charlson 
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comorbidity index was 0.21 (standard deviation [sd] = 0.78); and mean daily morphine 
milligram equivalent (MME) was 34.10 (95% CI: 34.08 - 34.12). Table 1 shows 
baseline characteristics for the patients included in the study; overall and by incident 
prescription opioid exposure during the index period. The average age of patients on 
incident daily use was 62.2 years (sd = 15.9) compared with 49.7 (18.2) years among 
non-daily users. The proportion of patients ages 65 and older was higher among 
incident daily users (49.7%) than among the non-daily users (24.3%). Overall, the 
proportion of patients on daily prescription opioid use increased progressively with 
age while the proportion of patients among non-daily users appeared to plateau after 
age 25 years. More than 55% of incident daily users had Medicare compared to only 
about a quarter of patients in the entire cohort. The southern US census region had the 
largest number of patients (about 40%), followed by the West and Midwest (23% 
each), while the Northeast had the fewest with only 11% of the sample residing in this 
region.  
Tobacco and alcohol were the most commonly used substances and were 
observed in 2.2% and 0.35% of the study cohort, respectively. For every 10,000 
patients in the cohort, 4 had at least one medical claim for an overdose during the 
index period; 2 out of 10,000 had at least one claim for an OUD; and 1 out of 10,000 
had at least one claim for an opioid overdose. Join and arthritis pain (15.2%) were the 
most common pain syndromes with a medical claim during the index period followed 
by back pain (7.5%). Almost 20% of patients had a pregnancy-related claim during the 
baseline period, 10% had a surgical claim, and 6% had a claim for a sprains and 
fractures. The proportion of patients who filled at least one antidepressant (13.4%) or a 
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benzodiazepine (7.3%) was much higher than the proportion of claims for a mental 
health disorder (6%). Overall, almost 90% of patients had no comorbid physical 
conditions. However, 20% of patients on incident daily prescription opioid had one or 
more comorbid physical conditions compared to 10% among non-daily incident 
prescription opioid users. Similarly, on average, the number of opioid prescriptions, 
number of different types used, daily MME, number of providers and pharmacies 
involved were higher among incident daily opioid users than non-daily incident opioid 
users. 
Patients were followed for up to 6 years (median of 2.5 years) with a total of 
11,294,819 person-years during which 39,417 (1%) died (Table 2). Overall crude 
death rate was 349 deaths per 100,000 person-years. Among incident daily 
prescription opioid users, the crude incidence rate of all-cause mortality was 1,476 per 
100,000 person-years compared to 317 per 100,000 person-years among non-daily 
users. The incidence rate difference (IRD) of 1,159 per 100,000 person-years 
represents the mortality rate among prescription opioid users that is attributable to a 
pattern of incident daily use, assuming daily users (i.e., exposed) would have had a 
mortality rate equal to non-daily users (i.e., unexposed) had they not been daily users. 
The crude rate of mortality among incident daily opioid users was 4.7 times that of the 
rate among incident non-daily users (crude incident rate ratio [IRR] = 4.66; 95% CI: 
4.655 - 4.659). The survival probabilities of patients with incident daily and non-daily 
exposure to prescription opioids are shown in Figures 3 and 4. Survival was associated 
with the initial pattern of prescription use (p-value < 0.0001). For the duration of the 
follow-up, incident daily users had lower survival rates than non-daily users with this 
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difference becoming more constant at later follow-up times. The differences persisted 
even after adjusting for potential confounders using inverse probability of exposure 
weights.  
Table 3 shows the results from the unadjusted and covariate adjusted-adjusted 
Cox regression models. In the unadjusted model, the hazard of all-cause mortality 
among patients on incident daily opioid users was 4.8 times the hazard among incident 
non-daily users (HR = 4.79; 95% CI: 4.55 - 4.84). After adjusting for baseline 
demographic and clinical variables, the hazard of death among patients with incident 
daily prescription opioid use was 2.6 times the hazard of all-cause mortality among 
patients with  incident non-daily prescription opioid use (HR = 2.57; 95% CI: 2.40 - 
2.75). The hazard was slightly attenuated over time (HR at 5 years = 1.86; 95% CI: 
1.72 - 2.02).   
DISCUSSION 
We found that an initial pattern of incident chronic opioid use increased risk the risk of 
all-cause mortality, even after adjusting for potential confounding factors measured at 
baseline. Almost 3% of our study population was exposed to incident daily 
prescription opioid use which was comparable to that found in previous studies.62 
About 27.8% of patients were exposed to at least one prescription opioid medication 
during a six-year period for which the data was available in the database of a 
commercially-insured population with Medicare Advantage customers. This is 
remarkably similar to a 2015 study that estimated that 92 million US adults used at 
least one prescription opioid medication, corresponding to about 30% of the adult 
population.63 Although incident daily prescription opioid users accounted for a 
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relatively small proportion of all prescription opioid users, it was associated with a 
significantly increased risk of all-cause mortality that may persist for many years after 
initiation of therapy. Previous studies have established that initial prescription opioids 
intended for short term use often lead to chronic use, and certain initial patterns of 
prescription opioid use have been associated with long-term use.64 Our study shows 
that incident daily use is associated with increased risk of all-cause mortality among 
insured adult patients taking prescription opioid medications for non-cancer, non-
palliative care treatment.  
Pain is one of the most challenging symptoms among patients with cancer or 
terminal illness and moderate-to-severe pain has been reported in up to 40% of dying 
patients.65 Analgesic medications including prescription opioids are often used to 
alleviate pain and discomfort in these settings.66 Because we excluded all patients with 
any claim for cancer diagnosis or palliative care at baseline or during the index period, 
it is unlikely that our findings are due to the use of prescription opioids for any of 
these indications. The risk of all-cause mortality was shown to last far beyond the 
index period which is as long as the usual six-month period used to define hospice 
care in clinical practice.  
There are several challenges to the design of a longitudinal observational drug 
study, including unmeasured confounding and confounding by indication, because the 
choice of treatment is often determined by disease severity, comorbid conditions, and 
physician preferences. Our analysis showed that incident prescription opioid users had 
more comorbid conditions and were on average, in poorer health conditions compared 
to non-daily prescription opioid users. After dealing with multicollinearity issues, we 
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constructed an adjusted model designed to reduce confounding using several 
approaches. First, no patients had absolute contra-indications to the study medication 
because all patients included in the study are known to have filled at least one opioid 
prescription at some point during the period covered by the database. Therefore, daily 
and non-daily prescription users in our study population represent the same study base. 
We applied the same inclusion and exclusion criteria to all patients, and the exposure 
of interest and the outcome were measured in a similar manner. Because both groups 
had comparable observation times, it is unlikely that censoring was related to the 
initial pattern of prescription opioid use. We adjusted for measured potential 
confounding variables, including the use of restrictive quadratic splines for continuous 
variables to allow for a non-linear relationship with time-to-all-cause mortality in our 
model. Patients with a known history of OUD were also excluded and we adjusted for 
OUD and opioid overdose diagnosed during the index period because continued 
opioid use after an overdose is associated with a higher risk of repeated overdose and 
death.67 Drug abuse, overdose, and OUD tend to occur at higher rates among long 
term opioid daily users.38 After adjusting for demographic characteristics, substance 
use disorders, psychiatric medication use, and other medical and surgical conditions at 
baseline, we found that incident prescription opioid use was associated with a higher 
rate of mortality that persists long after treatment was initiated. Despite these 
challenges, to the best of our knowledge, this is one of the largest observational 
studies of the association between patterns of opioid use and mortality carefully 
designed to emulate the essential tenets of a randomized trial.68 
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Pain is a common symptom among patients seen in office and emergency room 
settings and prescription opioid analgesics can be beneficial in when used 
appropriately. There is very little evidence of long term benefits for chronic non-
cancer pain or palliative care and several studies have reported significant risks 
associated with chronic opioid therapy.6,7,69,70 Initial patterns of prescription opioid use 
are associated with long-term use which in turn is associated with increased risks of 
adverse health outcomes.17,38 Prescription opioid-related deaths among patients on 
opioids are associated with the use of long-acting agents, use high dose therapy, 
concurrent use of benzodiazepines and gabapentin, and use in high risk settings such 
as sleep disorder, COPD, renal and liver failure, and elderly patients. Among patients 
ages 66 and older living in the community with chronic pulmonary disease, incident 
prescription use has been associated with increased risk of 30-day all-cause 
mortality.71,72 A recent study reported an increased risk of infection with current 
prescription opioid use, especially among new users.73 This suggests that there are 
several pathways to increase risk of death among patients on prescription opioids, 
especially new users on chronic therapy. 
LIMITATIONS 
The results of this study should be considered with certain study limitations in mind. 
First, we lacked data on socioeconomic status, and this likely limited our ability to 
include a sufficient set of covariates to adjust for confounding. For example, for the 
first time in nearly a quarter century, life expectancy decreased in the US in 2015, 
disproportionately affecting black men.74,75 Racial differences in rates of opioid-
related deaths have been well-documented.76 Second, we assumed that patients were 
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opioid-naive if they did not fill any opioid prescription during the baseline period 
although this may not imply that they were never exposed to opioids previously. 
Third, some patients may not have used their opioid prescription as recommended by 
the prescriber, and that any excess opioid medications from a previous prescription 
filled were completed before a subsequent prescription was taken.38 Fourth, although 
outpatient pharmacy data reflect a complete and accurate representation of 
prescription opioid utilization, we did not account for prescriptions paid for in cash 
that may not be captured in the database. Lack of information of prescription opioid 
use at other health plans or prior to start of the database may have led to 
misclassification of some prevalent prescription users as incident user. Such 
misclassification was minimized by at least 6 months of enrollment with medical and 
pharmacy benefits prior to the index date. Fifth, ICD-9 and ICD-10 codes in 
administrative data may lack sensitivity and specificity in identifying certain lifestyle 
medical conditions such as tobacco and alcohol use.  
CONCLUSIONS 
A small but significant proportion (3%) of all opioid-naïve patients became incident 
daily prescription opioid users within the first 6 months of opioid therapy. Incident 
chronic opioid use was associated with a 2.6-fold increased risk of all-cause mortality 
that persisted for up to 5 years after the prescription opioid regimen was first started. 
Our findings are consistent with current CDC guidelines to use the lowest effective 
prescription opioid dose for the shortest duration of treatment possible, especially 
among opioid-naïve patients.  
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Table 1. Characteristics of patients exposed to prescription opioid analgesics by initial  
patterns of use, 2010-2015 (N=4,005,001) 
  Initial pattern of prescription opioid use 
 
Patients characteristics 
Overall 
n = 4,005,001 
Non-daily users 
n=3895467 
Daily users 
n=109,534 
Observation time in days, mean (SD) 
Observation time in months, mean (SD) 
Charlson comorbidity index (95% CI) 
Female, n (%) 
Age in years, mean (SD) 
1030 (503) 
33.85 (16.53) 
0.21 (0.78) 
2194524 (54.79) 
50.0 (18.2) 
1030 (502) 
33.84 (16.50) 
0.20 (0.76) 
2134152 (54.79) 
49.7 (18.2) 
1037 (527) 
34.08 (17.31) 
0.47 (1.23) 
60372 (55.12)a 
62.2 (15.9) 
Age group, years 
18-24  
25-34  
35-44  
45-54  
55-64  
65+ 
 
388777 (9.71) 
562621 (14.05) 
657303 (16.41) 
736835 (18.40) 
659129 (16.46) 
1000336 (24.98) 
 
387082 (9.94) 
557361 (14.31) 
648129 (16.64) 
719801 (18.48) 
637145 (16.36) 
945949 (24.28) 
 
1695 (1.55) 
5260 (4.80) 
9174 (8.38) 
17034 (15.55) 
21984 (20.07) 
54387 (49.65) 
Insurance type, n (%) 
Commercial 
Medicare  
 
3040275 (75.91) 
964726 (24.09) 
 
2992684 (76.82) 
902783 (23.18) 
 
47591 (43.45) 
61943 (56.55) 
US census region, n (%) 
Midwest  
Northeast 
South  
West 
 
932474 (23.28) 
456427 (11.40) 
1701972 (42.50) 
914128 (22.82) 
 
911637 (23.40) 
444834 (11.42) 
1656377 (42.52) 
882619 (22.66) 
 
20837 (19.02) 
11593 (10.58) 
45595 (41.63) 
31509 (28.77) 
Substance use and misuse, n (%)    
Drug abuse 
OUD 
Overdose  
Opioid overdose 
Alcohol abuse 
Tobacco use 
Cocaine  
Marijuana    
Other substance usec 
2472 (0.06) 
937 (0.02) 
1750 (0.04) 
298 (0.01) 
14195      (0.35) 
88034 (2.20) 
689 (0.02) 
653 (0.02) 
1574 (0.04) 
2087 (0.05) 
756 (0.02) 
1592 (0.04) 
254 (0.01) 
13395 (0.34) 
84144 (2.16) 
646 (0.02) 
642 (0.02) 
1450 (0.04) 
385 (0.35) 
181 (0.17) 
158 (0.14) 
44 (0.04) 
800 (0.73) 
3890 (0.55) 
43 (0.04) 
11 (0.01)b 
124 (0.11) 
Pain-related diagnosis, n (%)    
Headaches/migraines 
Neck pain 
Back pain 
Abdominal pain 
Joint pain/arthritis 
Fibromyalgia/CFS 
Chronic pain syndromes 
Other pains 
119384 (2.98) 
134125 (3.35) 
298656 (7.46) 
220595 (5.51) 
608509 (15.19) 
59420 (1.48) 
170959 (4.27) 
130927 (3.27) 
115542 (2.97) 
128184 (3.29) 
282741 (7.26) 
214361 (5.50) 
582989 (14.97) 
55787 (1.43) 
157942 (4.05) 
125292 (3.22) 
3842 (3.51) 
5941 (5.42) 
15915 (14.53) 
6234 (5.69) 
25520 (23.30) 
3633 (3.32) 
13017 (11.88) 
5635 (5.14) 
Comorbid conditions, n (%)    
Fractures/strains 
Surgical diagnosis 
Pregnancy-related diagnosis 
Mental health disordersd 
234806 (5.86) 
387083 (9.66) 
748729 (18.69) 
252554 (6.31) 
226901 (5.82) 
377179 (9.68) 
722608 (18.55) 
240685 (6.18) 
7905 (7.22) 
9904 (9.04) 
26121 (23.85) 
11869 (10.84) 
Abbreviations: OUD=Opioid use disorder, SD=standard deviation, CI=confidence interval,  
ap-value = 0.03; bp-value > 0.05; all other p-values < 0.0001. 
cIncludes anxiolytics, stimulants, hallucinogenic drugs, or abuse of unspecified drugs. 
dIncludes adjustment disorders, anxiety disorders, conduct disorders, cognitive disorders, mood disorders, 
schizophrenia and psychotic disorders, alcohol-related disorders, substance-related disorders, and miscellaneous 
mental health disorders. 
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Table 1 (cont’d) 
  Initial pattern of prescription opioid use 
 
Patients characteristics 
Overall 
n = 4,005,001 
Non-daily users 
n= 3895467 
Daily users 
n = 109,534 
Use of Psychotropic medications, n 
(%) 
   
Benzodiazepines 
Antidepressant  
Antipsychotics 
Gabapentin 
290253 (7.25) 
536709 (13.40) 
45406 (1.13) 
42847 (1.07) 
275774 (7.08) 
505780 (12.98) 
41450 (1.06) 
37116 (0.95) 
14479 (13.22) 
30929 (28.24) 
3956 (3.61) 
5731 (5.23) 
Characteristics of opioid prescriptions 
during index period, mean (SD) 
   
Number of prescriptions 
Number of prescription types 
Number of providers involved 
Number of pharmacies used 
Average daily dose, MME 
Average daily MME, n (%) 
<50  
50-90  
>90 
1.73 (1.62) 
1.17 (0.44) 
1.29 (0.65) 
1.13 (0.42) 
34.10 (17.93) 
 
344707 (83.51) 
614103 (15.33) 
46191 (1.15) 
1.58 (1.18) 
1.16 (0.41) 
1.26 (0.60) 
1.12 (0.38) 
34.20 (17.43) 
 
3248793 (83.40) 
604119 (15.51) 
42555 (1.09) 
7.13 (4.13) 
1.65 (0.83) 
2.12 (1.41) 
1.58 (0.98) 
30.41 (30.41) 
 
95914 (87.57) 
9984 (9.11) 
3636 (3.32) 
Charlson comorbidity index, n (%) 
0 
1+  
 
3578382 (89.35) 
426619 (10.65) 
 
3490743 (89.61) 
404724 (10.39) 
 
87639 (80.01) 
21895 (19.99) 
Abbreviations: OUD=Opioid use disorder, SD=standard deviation, CI=confidence interval, MME=morphine 
milligram equivalents 
ap-value = 0.03; bp-value > 0.05; all other p-values < 0.0001. 
cIncludes anxiolytics, stimulants, hallucinogenic drugs, or abuse of unspecified drugs. 
dIncludes adjustment disorders, anxiety disorders, conduct disorders, cognitive disorders, mood disorders, 
schizophrenia and psychotic disorders, alcohol-related disorders, substance-related disorders, and miscellaneous 
mental health disorders. 
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Table  2.  Number of deaths and person-years of observation among cohort of patients 
initially exposed to prescription opioid daily and non-daily for non-cancer, non-palliative  
care conditions, 2010-2015 (N=4,005,001) 
 Initial pattern of prescription opioid exposure 
 Daily users Non-daily users Total 
Number of Deaths, n (%) 
Person-years of observation 
Crude Mortality Rate  
4,592(4.19) 
311,000.79 
1476.52 
34,825 (0.89) 
10,983,818.58 
317.06 
39,417 (0.98) 
11,294,819.38 
348.98 
Crude IRR (95% CI) 
Crude RD (95% CI)a 
4.66 (4.655, 4.659) 
1,159.47 (1159.466, 1159.467) 
 
Abbreviations: IRR=incidence rate ratio, IRD=incidence rate difference, CI=confidence interval 
aCases/100,000 person-years 
 
 
 
 
Table 3. Unadjusted and adjusted hazard ratios for all-cause mortality associated with exposure to 
incident daily prescription opioid use versus non-daily incident prescription opioid use, 2010-2015 
(N=4,005,001) 
 Daily opioid users 
n=109,534 
Non-daily opioid users 
n=3,895,467 
Overall 
n=4,005,001 
Deaths, n (%) 
Person-years of observation 
4,592 (4.19) 
311,000.79 
34,825 (0.89) 
10,983,818.58 
39,417 (0.98) 
11,294,819.38 
Unadjusted  Hazard ratio (95% CI) 4.79 (4.55, 4.84) Reference … 
Adjusted  Hazard ratio (95% CI)a 
Risk at baseline 
6-months risk 
1-year risk 
2-years risk 
3-years risk 
4-years risk 
5-years risk 
 
2.57 (2.40, 2.75) 
2.23 (2.08-2.40) 
2.12 (1.97, 2.28) 
2.00 (1.86, 2.16) 
1.94 (1.79, 2.10) 
1.90 (1.75, 2.06) 
1.86 (1.72, 2.02) 
 
Reference 
…. 
…. 
…. 
…. 
…. 
…. 
 
…. 
…. 
…. 
…. 
…. 
…. 
…. 
Abbreviations: CI=confidence interval 
aModel adjusted for differences in age, sex, US census region, index year, Charlson comorbidity index, substance 
use disorders (alcohol, Smoking, opioid overdose, opioid use disorder), surgical procedure, fracture and strains, 
pain conditions (headache, neck and jaw pain, back pain, abdominal pain, fibromyalgia), psychiatric medications 
(benzodiazepines, antidepressants, gabapentin) measured at baseline and index periods and , and number of 
opioid providers and average daily prescription opioid dose during the index period. 
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4,005,001 patients & 14,163,656 Rx 
9,737,104 patients & 60,040,979 Rx 
 
Exclude for age < 18 or > 90 years (n=425,687 patients) 
Exclude bulk agents (n=1,611 patients) 
Exclude for irregular prescription information (n=172,685)  
Quantity dispensed ≤ 0 or > 1000 
Days supplied ≤ 0 or > 180 
Ratio of quantity dispensed to days supplied > 20 
 Fill date before effective eligibility date 
  
9,735,493 patients & 60,021,642 Rx 
9,309,806 patients & 59,343,512 Rx 
4,026,599 patients & 14,254,253 Rx 
 
4,035,453 patients & 14,292,795 Rx 
 
4,043,232 patients & 14,358,680 Rx 
 
 
 
4,043,938 patients & 14,370,641 Rx 
9,261,186 patients & 59,342,622 Rx 
Death before start of follow-up (n=1,850 patients) 
Missing US census region (n=19,231 patients) 
Missing sex (n=517 patients) 
Excluded if index opioid Rx is for OUD (n=48,620 
i ) 
OUD diagnosis before index date (n=706 patients) 
Continuous enrollment for 6 months before  
& after index Rx date (n=5,217,248 patients) 
4,006,851 patients & 14,168,294 Rx 
Cancer diagnosis at baseline (n=7,779 patients) 
Hospice/palliative care claim at baseline 
 (n=8,854 patients) 
4,026,082 patients & 14,251,814 Rx 
AHFS class code used to identify opioid prescription claims in database  
N=9,909,789 patients claimed at least one opioid prescription  
between January 1, 2010 – December 31, 2015. 
(Total number of opioid prescriptions = 60,579,588) 
 
Figure 1. Study population and Sample Selection from all patients who had at least 
one opioid prescription, 2010-2015 
 
 
 
 
32 
 
 
 
 
 
 
 
  Index opioid prescription 
Insurance starts    Follow-up begins 
        Baseline period              Index period 
0   6   12 study time (months) 
   
Figure 2.  Study timeline for patient selection  
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Figure 3. Unweighted (upper panel) and inverse probability of exposure weighted 
(lower panel) Kaplan-Meier Curves shoeing the survival experience of daily and non-
daily prescription opioid users, 2010-2015.  
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Figure 4. Log-Log of the Survival curves showing daily and non-daily users 
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ABSTRACT 
BACKGROUND: Overuse and misuse of prescription opioids is associated with 
increased morbidity and mortality and places a significant cost burden on health 
systems.  
OBJECTIVE: To estimate annual statewide spending for prescription opioids in 
Rhode Island. 
METHODS: A cross-sectional study of opioids dispensed from retail pharmacies 
using data from the Rhode Island Prescription Drug Monitoring Program (PDMP) was 
performed. The study sample consisted of 651,227 opioid prescriptions dispensed to 
197,062 patients between January 1, 2015, and December 31, 2015. The mean, 
median, and total cost of opioid use was estimated using prescription dispensings and 
patients as units of analysis. A generalized linear model with gamma distribution with 
an identity link function, and separately with a log link function, was used to estimate 
the absolute and relative differences in per-patient annual adjusted average opioid 
prescription cost, respectively, by potential predictors.  
RESULTS: The estimated 2015 annual expenditure for opioid prescriptions in Rhode 
Island was $44,271,827. The average and median costs of an opioid prescription were 
$67.98 (SD $210.91) and $21.08 (quartile 1 to quartile 3 = $7.65-$47.51), 
respectively. Prescriptions for branded opioid products accounted for $17,380,279.05, 
which was approximately 39.3% of overall spending, although only 6% of all opioids 
dispensed were for branded drugs. On average, patients aged 45-54 years and 55-64 
years had overall adjusted spending for opioids that were 1.53 (95% CI = 1.491.57) 
and 1.75 (95% CI = 1.71-1.80) times higher than patients aged 65 years and older, 
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respectively. Per patient Medicaid and Medicare average annual spending for opioid 
prescriptions were 1.19 (95% CI = 1.16-1.22)  and 2.01 (95% CI = 1.96-2.06) times 
higher than commercial insurance  spending, respectively. Annual opioid prescription 
spending was 2.01 (95% CI = 1.98-2.04) and 1.50 (95% CI = 1.45-1.55) times higher 
among patients who also had at least 1 dispensing of a benzodiazepine or 
sympathomimetic stimulant, respectively. Average total spending for prescription 
opioids per patient increased with the average daily dosage: from 3-fold for patients 
using 50-90 morphine milligrams equivalent (MME) daily to 22-fold for those 
receiving 90 or more MME daily compared with those receiving less than 50 MME 
daily.  
CONCLUSIONS: This study provides the first estimate of the statewide direct cost 
burden of prescription opioid use using PDMP data and standardized pricing 
benchmarks. Total annual cost increased with age up to 65 years, mean daily dose, and 
concurrent use of benzodiazepines or stimulants. Commercial insurance bore the 
majority of the cost of prescription opioid use, but cost per patient was highest among 
Medicare beneficiaries. In addition to reducing harms associated with opioid overuse 
and misuse, substantial cost savings could be realized by reducing unnecessary opioid 
use, especially among middle-aged adults. 
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SUMMARY BULLETS 
 
What is already known about this subject 
 
What is Already Known About This Subject: 
• The overuse and misuse of prescription opioids is associated with increased 
morbidity and mortality, and places a significant cost burden on health 
systems. In 2005, White et al estimated that the total healthcare costs per 
patient were about 8.5 times higher among patients with a diagnosis of opioid 
use disorder compared to similar patients without a history of opioid use 
disorder1. 
• The total United States (U.S.) spending for opioid analgesic prescriptions 
increased substantially from $2.3 billion in 1999 to $7.4 billion in 2012. 
• The total annual expense for prescription opioid utilization in the outpatient 
setting in the U.S. in 2012 has been estimated at approximately $9.0 billion, 
representing an increase of 120% from 2002. 
• In 2016, the total annual expense for almost 18 million prescription drugs were 
filled at retail pharmacies in Rhode Island was about $1.2 billion.   
 
What This Study Adds:  
• Total annual retail expenditure for opioid analgesic prescriptions in Rhode 
Island for 2015 is estimate at $44,271,827. 
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• Total annual per-patient cost for opioid prescriptions is $17.65 higher among 
adults age 45-54 years, and $28.47 higher among patients of age 55-64 years as 
compared with those ages 65 years or older. 
• Commercial insurance bears the majority of the cost of prescription opioid use 
but cost per patient is highest among Medicare beneficiaries. 
• More than 10% of patients paid for at least one opioid prescription with cash 
but cash payment accounts for only 5.1% of the total annual prescription 
opioid expenditure. 
• Among patients who also received prescriptions for benzodiazepines, annual 
cost for opioid dispensings was approximately twice as such as patients who 
did not receive benzodiazepines; while among patients who also received 
prescriptions for stimulants, annual cost for opioid dispensings was 
approximately 50% higher as compared with patients who did not receive 
stimulants.  
INTRODUCTION AND BACKGROUND 
Pain is one of the most common reasons for an outpatient office visit.1-3 According to 
a 2011 Institute of Medicine report, approximately 100 million adults in the United 
States suffer from chronic pain each year.4 Prescription opioid analgesics are 
commonly used to treat a variety of painful conditions that range from acute injury to 
palliative care for terminal illness. In 2012, U.S. health care providers issued over 259 
million opioid prescriptions.5 Higher rates of opioid prescribing over the past 2 to 3 
decades may be attributed in part to historical changes in pain management guidelines, 
the Joint Commission requirements for routine pain assessment, promotion by the 
 
40 
 
pharmaceutical industry, and changes in reimbursement and out-of-pocket payment 
for prescription opioids.6-10  
Although use of prescription opioid analgesics is often clinically necessary, 
their addictive and euphoric properties easily result in misuse and often lead to opioid 
use disorders. In recent years, deaths from drug overdose have increased dramatically, 
exceeding the number of deaths from motor vehicle accidents, and have become the 
leading cause of accidental death in the United States.5,11-13 In 2015 alone, drug 
overdose was responsible for 52,404 deaths, with 33,091 (63.2%) associated with 
opioids. More than 60% of opioids involved in drug overdose deaths are prescription 
opioids.14,15 Benzodiazepines and opioids are often prescribed together, which has the 
potential risk of respiratory depression and overdose death.16-18 The U.S. Food and 
Drug Administration recently issued a boxed warning limiting the concurrent use of 
opioids and benzodiazepines or other central nervous system depressants, adding to 
recent changes in opioid prescribing guidelines.19-21  
Currently, all state legislatures, with the exception of Missouri, have 
implemented state-run prescription drug monitoring programs (PDMPs) that are 
designed to identify and track the prescribing and dispensing of controlled substances, 
including prescription opioids dispensed from retail pharmacies. The purpose of these 
PDMPs is to alert prescribers of controlled substances issued by other practitioners 
and to promote appropriate prescribing practices by making opioid medication history 
accessible to prescribers and pharmacists at the point of care delivery.22 In most states, 
including Rhode Island, prescription drugs that are monitored are classified as 
Schedule II, III, and IV and opioid medications within Schedule V on the Drug 
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Enforcement Administration’s (DEA) 5-tiered schedule. Drugs are assigned to 1 of 
these categories by the DEA based on their medicinal value and the potential for abuse 
and diversion.  
While significant attention has been directed towards the health consequences 
of opioid prescribing, little has been published on the associated health care costs.14,23-
25 The annual societal cost of pain in terms of medical care and lost productivity in the 
United States has been estimated at $635 billion in 2010 dollars.4 White et al. (2005) 
estimated that the total health care costs per patient varied from $15,884 to $18,388 
among patients with opioid use disorder diagnoses compared with only $1,830-$2,210 
among a similar group of patients with no documented history of such disorders.26 
Recent publications of costs related to opioid use have examined trends in 
expenditures using national Medicare and Medical Expenditure Panel Survey data.23,27 
Zhou et al. (2016) estimated that total U.S. spending for opioid analgesic prescriptions 
increased substantially from $2.3 billion in 1999 to $7.4 billion in 2012,27 while 
Stagnitti et al. (2015) estimated the total expenses for outpatient prescription opioids at 
$9.0 billion in 2012, an increase of 120% from 2002.28 
The effect of opioid use on statewide health systems can be quantified in terms 
of the direct cost of prescriptions to payers. To date, no published studies have 
examined state-level direct costs associated with prescription opioid dispensings from 
retail pharmacies across different age groups, gender, medication types, and sources of 
payment. In this study, data from the Rhode Island PDMP were used to estimate the 
distribution of the direct cost of opioid prescriptions dispensed by retail pharmacies in 
Rhode Island during the calendar year 2015.  
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  The goal of this analysis was to determine the total 2015 annual expenditure 
for prescription opioid analgesics in Rhode Island as captured in the PDMP. The 
proportions of spending associated with cash payment and by public and private 
payers were determined. In addition, we evaluated if gender, age group, payment type, 
or use of benzodiazepines or stimulants were associated with the total annual 
prescription opioid cost per patient. Understanding these factors may help elucidate 
the extent of opioid use statewide and provide support for efforts by providers, public 
health regulators, and payers to reduce the misuse of prescription opioid analgesics.29 
METHODS 
Study Design and Data Source: A cross-sectional study was conducted to examine 
annual opioid use and spending by patient and by type of opioid medication dispensed 
using data from the 2015 Rhode Island PDMP. For this study, opioid medication 
included all DEA Schedule II-IV prescription medications dispensed by retail 
pharmacies licensed within the state.  
Since June 28, 2016, Rhode Island state law requires pharmacies to monitor 
Schedule II-V controlled substances. Pharmacies holding a retail license in Rhode 
Island are legally required to electronically report all monitored controlled substances 
filled within 1 business day of the prescription being dispensed to the patient. This 
requirement includes independent pharmacies, chain pharmacies, food stores, and 
mass merchandisers but not substance abuse treatment programs, in-patient hospital 
pharmacy services, and correctional facilities. A commercial vendor links multiple 
prescriptions for each patient using probabilistic techniques based on the patient’s 
name, date of birth, and street address.30,31 Similarly, all prescriptions written by each 
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provider and dispensed by the pharmacist are linked by unique prescriber DEA 
numbers.  
The data provided by the Rhode Island Department of Health for our study 
included only de-identified patient, prescriber, and dispensing pharmacy information. 
Available information included patient age (in years), gender, a unique prescriber and 
dispensing pharmacy identifier, the National Drug Code (NDC) number, product 
name, strength, formulation, and therapeutic class code of each prescription, as well as 
the number of days supplied, metric quantity dispensed, method of payment, and date 
the prescription was filled. The pharmacist estimated days supply based on the 
quantity prescribed and the daily dosage. The payment type field was populated by the 
dispensing pharmacist, and a payment type of “commercial” was presumably 
incorrectly assigned for many older adults who were more likely enrolled in a 
Medicare plan. Therefore, for patients who were aged 65 years or older with a 
payment type of commercial, their payment type was reclassified as Medicare. 
Cohort Selection: All individuals with at least 1 prescription dispensing of any 
Schedule II-IV controlled substance were first identified. There were 2,058,816 
controlled substance prescriptions dispensed at retail pharmacies in 2015, including 
opioid analgesics, benzodiazepines, stimulants, skeletal muscles relaxants, and sleep 
aids. All prescriptions for non-opioid agents were first excluded (Figure 1); 
buprenorphine-containing products were excluded, since they are typically indicated 
for substance and opioid use disorder treatment; tramadol was also excluded because it 
is considered a mixed opioid-like analgesic32,33; and compounded formulations and 
bulk containers for which standardized pricing benchmarks were unavailable were 
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excluded. Opioid medications were classified by drug type using NDC numbers. The 
analytic sample consisted of 651,227 opioid prescriptions dispensed to 197,062 
patients from retail pharmacies in Rhode Island between January 1, 2015, and 
December 31, 2015. The U.S. Census Bureau estimated the population of Rhode 
Island to be 1,056,298 in 2015.34 An opioid prescription dispensing was defined as any 
prescription drug filled at a retail pharmacy and sold to a patient or patient’s agent on 
a particular day, whether a new or refilled prescription. 
To determine the unit price of each opioid prescription, NDC numbers for 
opioid dispensings were first matched with the 2015 Rhode Island Medicaid 
Maximum Allowable Cost (MAC) listing as the default unit price for branded and 
generic products. For sole source (i.e., branded) products and other NDC numbers that 
did not match the Medicaid MAC listing, pricing data from RED BOOK Online  
(Truven Health Analytics, Ann Arbor, MI) was used, which provided the average 
wholesale price (AWP) and federal upper limit (FUL) prices during 2015. These costs 
were assigned using the lesser of AWP-14% or FUL. The discounting of AWP was 
determined in consultation with experts in the field as a conservative estimate of drug 
costs. Sources of payment reported included cash (private pay), commercial insurance, 
Medicare, Medicaid, and other (i.e., worker’s compensation, Indian Health Service, 
the Veterans Health Administration, Tricare, and other federal sources).  
We hypothesized that the total annual expenditure for opioid prescriptions was 
associated with the use of benzodiazepines or stimulants, use of higher daily doses of 
opioids, and use of multiple providers and pharmacies. This study determined if opioid 
prescription expenditure was associated with patient age groups, gender, or payment 
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type. Use of benzodiazepines or stimulants was defined as the use of 1 or more 
prescriptions of either a benzodiazepine or a stimulant within the study year. The 
dosage of each prescription opioid dispensed was converted to its morphine milligram 
equivalent (MME) per day using NDC-based conversion factors published by the 
Centers for Disease Control and Prevention’s National Center for Injury Prevention 
and Control in June 2015.35-38 Less than 1% of opioid prescriptions did not have 
enough information to calculate the daily MME. Finally, a measure of potential health 
system abuse was defined as patients who received prescriptions for opioids from 5 or 
more prescribers and filled by 5 or more pharmacies within the 12-month period 
(called 5/5/12 criteria)—referred to as multiple provider episodes (MPE) or  
“doctor shopping.”39  
Statistical Analysis: The mean, median, and total costs of opioid use were estimated 
using opioid prescription dispensings and patients as units of analysis. All costs were 
retained in 2015 U.S. dollars. The last opioid prescription received during the study 
year was used to identify the most recently used opioid type and and to assign 
medication type and source of payment when patients were used as the unit of 
analysis. We determined overall annual spending for opioid medications and further 
categorized spending by age group (aged < 18, 18-24, 25-34, 35-44, 45-54, 55-64, and 
65+ years); gender; medication type; and payment type. Annual cost values were non-
normally distributed with a large right skew (skewness = 22.66). 
With patients as the unit of analysis, a generalized linear model with gamma 
distribution with an identity link function, and separately with a log link function, was 
used to estimate the absolute and relative differences in per-patient annual adjusted 
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average prescription opioid cost, respectively, by potential predictors.40,41 Independent 
variables included in the model were age group, gender, payment type, mean daily 
MME per patient, use of benzodiazepines or stimulants, and conditional on the link 
function. The gamma family was selected, which has a constant coefficient of 
variation and assumes that the variance is proportional to the square of the mean.41,42 
All analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC), and all 
statistical tests were 2-sided and performed at the 0.05 significance level. This study 
was approved by the institutional review board at the University of Rhode Island.  
RESULTS 
The study population consisted of 197,062 patients who filled a total of 651,227 
opioid prescriptions in 2015. This number represents an estimated 18.7% of patients in 
Rhode Island who received at least 1 dispensing for an opioid medication from a retail 
pharmacy during 2015. Approximately 56% of patients who filled at least 1 opioid 
prescription were female (Table 1). About 23.9% of patients were aged 65 years and 
older, and 38.3% were aged 45-64 years. Based on the last opioid prescription 
dispensed, most patients were prescribed either hydrocodone or oxycodone (83.1%). 
Approximately 58.2% of patients had commercial insurance; 21.9% were covered by 
Medicare; and almost 10% of patients paid for their prescriptions using cash. More 
than 90% of patients used only 1 method of payment during the study year. A 
subgroup analysis of cash payment for all opioid prescriptions showed that 21,538 
patients used cash payment for least 1 opioid prescription in 2015. Among them, 
16,240 (75.40%) patients used only cash payment for all opioid prescriptions filled at 
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the retail pharmacy, while 5,298 (24.60%) patients used 2 or more types of insurance 
payment during the same calendar year (Appendix A, available in online article). 
The total 2015 annual retail expenditure for opioid prescriptions in Rhode 
Island was estimated at $44,271,827, which corresponded to an average spending of 
$3.7 million per month. The average and median costs of an opioid prescription were 
$67.98 (standard deviation [SD] $210.91) and $21.08 (quartile 1 to quartile 3 [Q1-Q3] 
= $7.65-$47.51), respectively. Both the number of opioid prescriptions dispensed and 
per patient annual spending increased with age but appeared to stabilize among 
patients aged 45 years or older (Table 2). The total annual prescription opioid 
spending for patients aged 45-64 years was estimated to be $26,337,403.49, which 
was not only proportionately higher compared with patients aged 65 years and older 
but also higher than spending for any other age group.  
Oxycodone and hydrocodone were the most commonly dispensed opioid 
prescriptions, accounting for more than 82% of all prescriptions filled. The total 
annual expenditure for these 2 drug types was approximately $32.5 million, which 
accounted for 73% of all opioid prescription spending. The average cost of an 
oxycodone prescription was approximately $50 more than hydrocodone, reflecting a 
dramatically higher cost for extended-release oxycodone compared with hydrocodone 
products, which were mostly dispensed in generic immediate release forms. The 
average and median costs of a prescription of oxymorphone were $595.72 (SD 
$512.60) and $439.68 (Q1-Q3 = $246.94-$779.81), respectively, making it the most 
costly opioid prescription type among branded and generic products.  
 
48 
 
  Branded opioid prescriptions were far more expensive than their generic 
counterparts. However, 94% of all opioid prescriptions were for a generic product, 
with an average price of $43.90 (SD $116.21) compared with $449.78 (SD $616.97) 
per branded prescription. Branded opioid prescriptions accounted for $17,380,279.05 
of the yearly total, which was about 39.3% of overall spending, although only 6% of 
all opioids dispensed were for branded drugs.  
Commercial insurance was the most common method of payment type for 
opioid prescriptions (51%), followed by Medicare (29.4%). Cash payment was used 
for 60,548 (9.3%) of all prescription opioids dispensed. We found that, on average, 
Medicare spent $85.31 (95% confidence interval [CI] = $84.24$86.39) per opioid 
prescription, which was significantly more than Medicaid and private insurance, 
which spent $52.15 (95% CI = $50.82-$53.48) and $65.55 (95% CI = $64.83-$66.28) 
per prescription, respectively. However, commercial insurance was responsible for 
49.3% of the total expenditure, while Medicaid and Medicare paid for only 6.1% and 
36.9%, respectively. Cash payment represented 5.1% of the annual spending.  
Table 3 presents the results of a generalized linear model. Using a gamma 
regression model with an identity link function, gender, age group, payment type, 
mean daily MME per patient, use of benzodiazepines or stimulants, and MPE were 
statistically significant predictors of total annual expenditure. Patients aged 45-54 
years and 55-64 years had overall adjusted mean spending for opioids that was $17.65 
(95% CI = $15.26$20.04) and $28.47 (95% CI = $26.06-$30.88) higher, 
respectively, than patients aged 65 years and older. As expected, the youngest patients 
had significantly lower adjusted total expenditure per patient compared with adults 
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aged over 65 years. With regard to method of payment, overall adjusted mean costs 
per Medicare and Medicaid patients were $33.20 (95% CI = $31.05-$35.35) and $0.56 
(95% CI = -$0.51-$1.63) higher, respectively, compared with commercially insured 
patients, while patients who used cash payments spent on average $3.80 less than the 
amount charged to customers with commercial insurance.  
Patients who were dispensed benzodiazepines (26.5%) or sympathomimetic 
stimulants (4.4%) had higher annual spending for opioid medications than those who 
did not receive these medications. On average, adjusted annual opioid prescription 
cost was $35.99 (95% CI = $34.45-$37.54) higher among patients who also received 
at least 1 benzodiazepine dispensing, while adjusted annual opioid prescription cost 
was also had at least 1 dispensing for a stimulant medication. As a statistically 
significant predictor of annual opioid expenditure, for patients with MPE, average 
adjusted annual cost of opioid prescriptions per patient was increased by 
approximately $863.58 (95% CI = $689.48-$1,037.68) compared with patients who 
did not meet this criteria. The adjusted annual total opioid spending per patient also 
increased substantially  with the use of higher daily doses of opioids, since average 
total cost was more than $337.73 (95% CI = $332.84-$342.62) greater among patients 
using on average more than 90 MME daily, compared with patients receiving on 
average of less than 50 MME daily. 
Using a gamma regression model with a log link function (Table 3), there was 
a 69% reduction in overall adjusted average cost per patient when comparing those 
who were aged 18 years or younger to those aged 65 years and older. Conversely, 
patients aged 45-54 years and 55-64 years had overall adjusted average spending for 
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opioids that were 1.53 (95% CI = 1.49- 1.57) and 1.75 (95% CI = 1.71-1.80) times 
higher, respectively, than patients aged 65 years and older. Per patient Medicaid and 
Medicare average adjusted annual spending for opioid prescriptions were 1.19 (95% 
CI = 1.16-1.22) and 2.01 (95% CI = 1.96-2.06) times higher than commercial 
insurance spending, respectively, while average spending per patient using cash 
payment was 17.4% lower than charges to commercial payers.  
Patients who were dispensed benzodiazepines or a sympathomimetic 
stimulants had higher annual spending for opioid medications than those who were 
not. On average, adjusted annual opioid prescription spending was 2.01 (95% CI = 
1.982.04) and 1.50 (95% CI = 1.45-1.55) times higher among patients who also had at 
least 1 benzodiazepine or stimulant dispensing, respectively. Average adjusted total 
spending for prescription opioids per patient increased with the average daily dosage: 
from 3-fold for patients using 50-90 MME daily to 22-fold for those receiving 90 or 
more MME daily compared with those receiving less than 50 MME daily. Patients 
with MPEs had mean adjusted annual opioid spending that was 4.34 (95% CI = 3.75-
5.02) times higher than patients who did not use multiple prescribers and pharmacies. 
DISCUSSION 
In 2015, 197,062 patients (an estimated 18.7% of the state’s population) received at 
least 1 dispensing for an opioid medication from a retail pharmacy in Rhode Island. 
The total number of opioid prescriptions filled was 651,227, which corresponds to an 
average of 3.3 prescriptions per resident per year, or an estimated opioid prescribing 
rate of 61.65 prescriptions per 100 residents. This rate is comparable to rates estimated 
for other neighboring states and the rest of the country.39,43  
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The direct cost burden of prescription opioids was determined using data from 
a statewide PDMP, capturing controlled substance dispensings at the pharmacy level 
and encompassed dispensings for all providers and payment types, including cash. 
Thus, estimates from this study provide results that are more generalizable to the 
overall population, compared with analyses of a particular payer’s pharmacy claims. 
Because PDMP programs do not include drug pricing information, this information 
was assimilated from other sources, providing what we believe is the first estimate of 
the direct annual cost burden of prescription opioid use, estimated at $44,271,827.00 
for a population of approximately 1 million, in 2015 U.S. dollars. This estimate 
represents about 3.7% of total prescription drug sales at retail pharmacies in Rhode 
Island for 2016, according to a report published recently by the Kaiser Family 
Foundation (2017).44 According to this report, which was based on IMS Health 
national prescription audit data, the total 2016 expenditure for all 18 million 
prescription drugs dispensed at retail pharmacies in Rhode Island was estimated at 
$1.2 billion. The estimate from our study does not include dispensings for tramadol, 
compounded products, or opioids dispensed in substance and opioid use disorder 
treatment centers, during inpatient hospital care, or in state correctional facilities.  
In our study, the cost associated with prescription opioid use was determined in 
part by the intensity of use (i.e., number of dispensings and daily dosage) and the 
opioid product prescribed. Patients aged 45-64 years accounted for 47.14% of all 
opioid prescriptions dispensed and 59.49% of the total expenditure. While mean costs 
were highest for prescriptions for oxymorphone ($595.72), levorphanol ($560.80), and 
tapentadol ($492.86), dispensings for these medications accounted for only 3.7% of 
 
52 
 
total overall annual cost. More than half (53.8%) of the annual cost of opioid 
medications for 2015 was associated with oxycodone dispensings, most of which can 
be attributed to higher-cost extended-release formulations, which accounted for almost 
50% of the total annual expenditure even though they represented only 11% of all 
prescriptions. Efforts to address the cost burden of opioid overuse might target this 
middle-aged subgroup, with a focus on reducing the long-term use of opioids, many of 
which are prescribed as higher-cost extended-release formulations. Evidence for the 
use of opioids for chronic pain is limited amidst mounting evidence of serious dose-
dependent harm.45 Decreasing the unnecessary use of extended-release oxycodone for 
treatment of acute pain and the availability of a less costly generic formulation of this 
medication would have a dramatic effect on opioid expenditure, potentially yielding 
significant savings to the health care system.  
Doctor-shopping behavior and the use of cash for prescription opioid payment, 
especially when the patient also has other types of insurance coverage, may indicate 
prescription opioid misuse.46 About 21,538 (10.93%) patients paid for at least 1 opioid 
prescription with cash during the 2015 calendar year, and approximately 25% of these 
patients used at least 1 other type of insurance to pay for opioid prescriptions during 
the same year. The overall adjusted average prescription opioid spending by the 409 
patients who met the 5/5/12 criteria was dramatically greater than that spent by 
patients who did not meet these criteria ($64.17 vs. $927.76, P < 0.001). However, 
higher costs associated with potential doctor shopping or use of benzodiazepines or 
stimulants may be an indication of poorly managed comorbid chronic conditions 
resulting from lack of coordinated care.  
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Other valid reasons for having multiple providers might include a change in 
primary care providers, different providers covering a patient’s usual prescriber, 
having multiple specialists, and visits to dentists or the emergency room.47 It is 
envisioned that the overuse of prescribers and pharmacies will decrease with 
increasing public awareness and implementation of regulations that require providers 
to review the PDMP before issuing a prescription for an opioid medication. However, 
most PDMPs are not currently integrated with electronic medical records, which make 
access to this information time consuming and often unfeasible.  
The finding in this study that nearly 1 in 5 state residents received at least 1 
opioid prescription during 2015 indicates that opioids are commonly prescribed within 
the state and suggests that a proportion of opioid prescribing may be clinically 
unnecessary. Levy et al. (2015) reported that opioids are the most commonly 
prescribed analgesics in the United States.48 This study, however, did not examine the 
clinical indications for which these opioid prescriptions were dispensed, so we could 
not quantify the extent and cost of inappropriate opioid prescribing. Liu et al. (2013), 
on the other hand, found that up to 40% of Medicaid patients receiving an opioid 
prescription had at least 1 marker of inappropriate prescribing, such as overlapping 
opioid prescriptions, overlapping opioid and benzodiazepine prescriptions, initiation 
of therapy with a long-acting opioid, use of long-acting opioids for acute pain, or high 
daily doses more than 90 MME.24  
The Centers for Disease Control and Prevention recently published guidelines 
for prescribing opioids for chronic pain in the absence of cancer, palliative, or terminal 
care.19 These guidelines recommend the use of non-opioids as first-line therapy for 
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chronic pain, using opioid analgesics only when the benefits of such therapy are likely 
to outweigh the risks and prescribing the lowest effective dosage for the shortest 
number of days, when needed. Many insurers have introduced new policies to reduce 
inappropriate opioid prescribing, such as drug utilization review, prior authorization, 
quantity limitations, and pharmacy management review programs.49,50 Trends in 
opioid prescribing should continue to be monitored as a measure of effectiveness of 
current public health interventions and narcotic stewardship programs, in order to 
determine if the frequency and cost burden of opioid use is diminishing. 
LIMITATIONS 
This study has some limitations to consider. The PDMP database does not include 
information describing health conditions or patient diagnoses, laboratory tests, 
clinician specialty, use of non-controlled prescription medications, or any other 
indicators of health care utilization. Since the analysis could not determine whether an 
opioid prescription was appropriate, we could not quantify the cost of inappropriate 
opioid prescribing, which limited the application of these results to improve 
prescribing practices.  
The total cost estimate does not represent the total cost burden, since we could 
not estimate the cost of adverse effects or account for opioid prescriptions not filled in 
retail pharmacies. Furthermore, estimates from this study are a general approximation 
because payer reimbursement rates may vary from the methods we applied in our 
analysis to some degree. Also, a patient’s state of residence could not be determined. 
However, the number of patients from neighboring states who received opioid 
prescriptions from Rhode Island pharmacies is likely to be offset by the number of 
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Rhode Island residents who filled opioid prescriptions at pharmacies in neighboring 
states.  
The payment type variable was poorly reliable with regard to capturing 
Medicare as a payment source. An undetermined number of older adults were 
misclassified as having commercial insurance, and while we attempted to address this 
issue by reassigning these patients as covered by a Medicare drug plan, our ability to 
make inferences regarding opioid expenditure, by Medicare Advantage plans in 
particular, was nevertheless limited.  
Finally, we recognize that the direct cost of prescriptions is merely 1 
component driving health system expenses associated with pain management and 
opioid use in particular. Consideration of other treatment modalities, medical care, and 
humanistic outcomes should be included in health economic analyses that assess 
opioid use as facet of pain management.  
 
CONCLUSIONS 
This study provides the first estimate of a statewide direct cost burden of prescription 
opioid use using PDMP data and standardized pricing benchmarks. Total annual cost 
increased with age up to 65 years, mean daily dose, and concurrent use of 
benzodiazepines or stimulants. Commercial insurance bore the majority of the cost of 
prescription opioid use, but cost per patient was highest among Medicare 
beneficiaries. Almost 11% of patients used cash payment at least once during the 2015 
calendar year, and cash payment accounted for about 5.1% of the total annual 
prescription opioid expenditure.  
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This analysis suggests that substantial cost savings could result from increased 
use of generic formulations of commonly prescribed opioid products. Greater savings 
and improved patient health outcomes could be realized by reducing overall opioid 
use, especially among middle-aged individuals. 
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Table 1 Characteristics of Individuals Who Filled at Least one Opioid Prescription at a  
Retail Pharmacy in R.I. in 2015 (N = 197,062)  
 
Characteristica n (% of N) 
 
Genderb 
Female  
Male 
 
110,001  (55.82) 
  87,043  (44.17) 
Age Group, Years 
less than 18 
18-24 
25-34 
35-44 
45-54 
55-64 
greater than 65 
 
5,995      (3.04) 
15,327    (7.78) 
27,302  (13.85) 
27,738  (14.08) 
37,155  (18.85) 
38,372  (19.47) 
45,173  (22.92) 
Payment Method 
Commercial Insurance   
Medicare 
Cash 
Medicaid 
Otherc 
 
114,654 (58.18) 
  43,213 (21.93) 
  19,476   (9.88) 
  15,767   (8.00) 
   3,952    (2.01) 
Most Recent Opioid Dispensed  
Hydrocodone 
Oxycodone 
Codeine-based 
Morphine 
Hydromorphone 
Fentanyl 
Methadone 
Tapentadol 
Oxymorphone 
Meperidine 
Pentazocine 
Butorphanol 
Otherse 
 
90,151  (45.75) 
73,622 (37.36) 
18,409 (9.34) 
  6,894 (3.50) 
  3,698 (1.88) 
  1,450 (0.74) 
     650 (0.33) 
     192 (0.10) 
     146 (0.07) 
       64 (0.03) 
       50 (0.03) 
       35 (0.02) 
    1,700 (0.86) 
Mean daily MME per patientf 
≤ 50 
50-90 
90+ 
 
153,085 (77.68) 
32,081 (16.28) 
8,536 (4.33) 
Benzodiazepine use 
No 
Yes 
 
144,899 (73.53) 
52,163 (26.47) 
Stimulant use 
No 
Yes 
 
188,343 (95.58) 
8,719 (4.42) 
5/5/12 criteria 
Not met 
met 
 
196,653 (99.79) 
409 (0.21) 
aGender, payment method, medication type and mean daily MME classified according to data captured in the last 
prescription dispensed in 2015. 
bGender was not reported for 18 patients (0.01%).  
dIncludes worker’s compensation, Indian Health Services, the Veterans Health Administration, Tricare, other federal 
sources. 
ePrimarily opioid-containing cough products and Levorphanol (see Appendix A) 
fMME=Morphine milligram equivalent; unable to determine MME for 3,360 (1.71%) of patients 
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Table 2. Opioid Prescriptions Dispensed in by R.I. Retail Pharmacies in 2015 
 
Characteristic 
Number of  
Prescriptions (%) 
 
Prescription Cost ($) 
% Total 
Cost 
   
      Mean (SD) 
 
Median 
 
Total 
 
Overall  651,227 67.98 (210.91) 21.08 44,271,827.00 100.00 
Age group, years 
less than 18 
18-24 
25-34 
35-44 
45-54 
55-64 
greater than 65 
 
    7,889   (1.21) 
  22,794   (3.50) 
  57,597   (8.84) 
  84,085 (12.91) 
144,608 (22.21) 
162,352 (24.93) 
171,902 (26.40) 
 
20.78   (41.63) 
15.45   (43.29) 
34.55 (145.80) 
61.08 (223.88) 
81.01 (247.86) 
90.07 (251.01) 
59.87 (154.39) 
 
8.54 
7.02 
9.36 
16.47 
22.95 
25.32 
22.95 
 
163,902.33 
352,063.77 
1,990,258.63 
5,135,736.95 
11,714,458.06 
14,622,945.43 
10,292,461.84 
 
0.37 
0.80 
4.50 
11.60 
26.46 
33.03 
23.25 
Medication type 
Butorphanol 
Codeine-based 
Fentanyl 
Hydrocodone 
Hydromorphone 
Levorphanol 
Meperidine 
Methadone 
Morphine 
Oxycodone 
Oxymorphone 
Pentazocine 
Tapentadol 
Othersa 
 
355 (0.05) 
37,100 (5.70) 
15,169 (2.33) 
253,850 (38.98) 
9,717 (1.47) 
9 (0.00) 
261 (0.04) 
7,156 (1.10) 
35,462 (5.45) 
281,225 (43.18) 
1,810 (0.28) 
341 (0.05) 
1,103 (0.17) 
7,669 (1.18) 
 
163.90 (109.88) 
6.86     (6.99) 
204.43 (552.01) 
34.15   (54.21) 
209.70 (554.09) 
560.08 (907.64) 
29.20   (24.95) 
41.82   (32.23) 
108.67 (267.76) 
84.69 (235.80) 
595.72 (512.60) 
173.27 (178.45) 
492.86 (293.16) 
63.64   (99.66) 
 
163.59 
4.43 
126.66 
21.42 
18.23 
103.12 
19.13 
29.70 
40.22 
21.18 
439.68 
178.75 
421.98 
38.16 
 
58,184.34 
254,557.96 
3,101,069.73 
8,668,532.13  
2,037,677.97 
5,040.76 
7,620.44 
299,254.81 
3,853,808.20 
23,817,051.40 
1,078,255.85 
59,084.86 
543,626.74 
488,061.81 
 
0.13 
0.57 
7.00 
19.58 
4.60 
0.01 
0.02 
0.68 
8.70 
53.80 
2.44 
0.13 
1.23 
1.10 
MME dailyb 
≤ 50 
50-90 
90+ 
 
430,519 (66.11) 
135,105 (20.75) 
81,145 (12.46) 
 
30.28   (53.62) 
70.26 (137.46) 
265.42 (513.27) 
 
14.39 
28.51 
87.73 
 
13,034,889.82 
9,492,612.15 
21,537,624.36 
 
29.44 
21.44 
48.65 
Generic or Brand name 
Generic 
Brand name 
 
612,585 (94.07) 
38,642   (5.93) 
 
43.90 (116.21) 
449.78 (616.97) 
 
19.13 
279.43 
 
26,891,547.96 
17,380,279.05 
 
60.74 
39.26 
Duration of action 
Short-acting 
Long-acting 
 
579,849 (89.04) 
71,378 (10.96) 
 
38.27 (128.72) 
309.36 (453.68) 
 
16.47 
136.26 
 
22,190,457.00 
22,081,370.01 
 
50.12 
49.88 
Payment typec 
Commercial 
Medicare 
Medicaid 
Private pay 
Otherd 
 
332,088 (50.99) 
191,554 (29.41) 
51,490   (7.91) 
60,548     (9.3) 
15,546   (2.39) 
 
65.55  (213.46) 
85.31  (240.12) 
52.15  (154.24) 
37.18    (97.84) 
78.72  (234.92) 
 
19.00 
28.08 
15.13 
14.39 
20.11 
 
21,769,832.09 
16,341,749.85 
2,685,118.58 
2,251,262.97 
1,223,849.24 
 
49.17 
36.91 
6.07 
5.09 
2.76 
aPrimarily opioid-containing cough products (see Appendix A) 
b MME=Morphine milligram equivalent; unable to determine MME for 1.71% of observations 
cIf age ≥ 65 and Commercial ins. then payment type was reclassified as Medicare; Method of payment was missing for 1 prescription. 
d Includes worker’s compensation, Indian Nation, the Veterans Health Administration, Tricare, other federal sources. 
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Table 3: Adjusted per-Patient Total Annual Prescription Opioid Costs by Patient 
Demographic and Utilization Characteristics (N=197,062) 
 
Independent variable 
Mean cost per patient ($)a 
[95% CI] 
Adjusted 
β-coeffb 
 
SE 
 
95% Conf. Interval 
Intercept 64.17      (62.25, 66.10) 3.8415 0.0136 (3.8149, 3.8680) 
Age group (years) 
 65 + 
less than 18 
18-24 
25-34 
35-44 
45-54 
55-64 
 
Reference 
-45.89 (-48.09, -43.68) 
-50.22 (-52.13, -48.31) 
-42.10 (-44.04, -40.17) 
-11.89   (-14.20, -9.59) 
    17.65     (15.26, 20.04) 
28.47     (26.06, 30.88) 
 
 
-1.1680 
-1.2910 
-0.7492 
-0.0415 
0.4257 
0.5621 
 
 
0.0243 
0.0173 
0.0150 
0.0149 
0.0139 
0.0137 
 
 
(-1.2157, -1.1204) 
(-1.3250, -1.2571) 
(-0.7786, -0.7198) 
(-0.0706, -0.0124) 
(0.3985,  0.4530) 
(0.5353,  0.5888) 
Gender 
  Female 
  Male 
 
Reference 
5.14          (4.44, 5.84) 
 
 
0.1364 
 
 
0.0070 
 
 
(0.1228, 0.1501) 
Payment typec 
  Commercial 
  Medicaid 
  Medicare 
  Private Pay 
  Otherd 
 
Reference 
0.56      (-0.51, 1.63) 
33.20  (31.05, 35.35) 
-3.80    (-4.69, -2.91) 
9.16    (5.17, 13.15) 
 
 
0.1733 
0.6971 
-0.1917 
0.2988 
 
 
0.0129 
0.0127 
0.0129 
0.0250 
 
 
(0.1481, 0.1986) 
(0.6722, 0.7220) 
(-0.2170,-0.1663) 
(0.2498, 0.3479) 
Mean daily MME per patient 
  ≤50 
  50-90 
  >90 
 
Reference 
97.91 (95.14, 100.68) 
 337.73 (332.84 , 342.62) 
 
 
1.0756 
3.1124 
 
 
0.0092 
0.0168 
 
 
(1.0575, 1.0938) 
(3.0795, 3.1453) 
Benzodiazepine usee 
  No 
  Yes (n = 52,163) 
 
Reference 
35.99 (34.45, 37.54) 
 
 
0.6980 
 
 
0.0079 
 
 
(0.6825, 0.7135) 
Stimulant usef 
  No 
  Yes (n = 8,719) 
 
Reference 
8.61 (6.47, 10.76) 
 
 
0.4062 
 
 
0.0167 
 
 
(0.3735,0.4390) 
5/5/12 Criteriaf 
  Not Met  
  Met (n = 409) 
 
Reference 
  863.58 (689.48, 037.68) 
 
 
1.4672 
 
 
0.0741 
 
 
(1.3220, 1.6125) 
aMean cost per patient estimated using the identity link function; 
bCoefficients of gamma regression and standard errors estimated using the log link function; 
c If age ≥ 65 and Commercial Ins. then payment method was reclassified as Medicare; 
d Includes worker’s compensation, Indian Nation, the Veterans Health Administration, Tricare, other federal sources; 
e,f Use of other benzodiazepines and stimulants defined as one of more prescriptions in a 12 month period.  
f 5/5/12/ Criteria: Opioid prescriptions from at least 5 different pharmacies and 5 different prescribers during the 12 month period.  
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Figure 1. Sample Identification Flowchart 
 
 
 
Schedule II-IV prescriptions dispensed 
by Rhode Island Retail Pharmacies in 
 ( ) 
 
Opioids prescribed for pain (N=764,441) 
 
Buprenorphine-containing products (N=44,850) 
 
True opioids (N=651,459) 
 
 
Tramadol (N=112,892) 
 
Analytic sample dispensing (N=651,227) 
 
Opioid-like agents (N=809,291) 
 
 
Non-opioids (N=1,249,525) 
 
Benzodiazepines (N=637,471)  
Stimulants (N=348,640) 
Others (N=263,414) 
Unique patients identified (N=197,062) 
Compounded and bulk products (N=232) 
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ABSTRACT 
Background: Prescription opioid misuse and overdose among patients on chronic 
opioid therapy (COT) is a serious public health problem in the United States. In 
response more state-run prescription drug monitoring programs (PDMP) have been 
implemented and strengthened. PDMP administrators and criminal investigators 
suggest that cash payment may be indicative of potential prescription opioid misuse 
(POM), but there is little systematic evidence to substantiate this claim.  
Objectives: To evaluate the association of methods of payment and potential 
prescription opioid misuse among patients on chronic opioid therapy.  
Methods: De-identified 2015 Rhode Island PDMP data was used to conduct a cross-
sectional study. We restricted the study cohort to patients on COT defined as having 
received at least 90 days’ supply during a 6-month period. The database captures 
information describing opioid dispensing at all R.I. retail pharmacies including 
sources of payment for each opioid prescription. The method of payment was 
categorized as no cash (insurance exclusively), cash only, or both (insurance with at 
least one cash payment). A modified validated opioid misuse index that combines the 
number of opioid prescribers and pharmacies used, and days’ supply of short-acting 
and long-acting opioids, was used to define potential prescription opioid misuse. A 
multivariable log-binomial regression model was used to examine the association 
between cash payment and potential opioid misuse, controlling for sex, age group, 
type of opioid used, and concurrent benzodiazepine use. The analysis was stratified by 
age group (patients under 65 years vs. patients 65 and over) because the pharmacy 
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benefit design for many Medicare Part D drug plans includes a coverage gap where 
patients pay cash for a limited period of time. 
Results: A total of 45,332 patients met our inclusion criteria for COT, of which 80% 
paid for all of their opioid prescriptions with third party insurance exclusively, 3% 
used only cash, and 17% had insurance and paid for at least one opioid prescription in 
cash. The median age was 57 years and 59% were female. Among patients under 65 
years old, those who had insurance coverage and paid for at least one of their opioid 
prescriptions in cash were more likely to exhibit a pattern of opioid filling suggestive 
of prescription opioid misuse as compared to those who paid all opioid prescriptions 
with insurance exclusively, after controlling for potential confounding variables 
(adjusted risk ratio [aRR] = 1.80; 95% confidence interval [CI]: 1.73, 1.87). Among 
patients aged 65 years and older, the strength of the association was differed by 
gender. Compared with men who used only insurance to buy their opioid prescriptions 
(reference group), the risk of potential POM was higher among women who had 
insurance and used cash payment (aRR=2.19; 95% CI: 2.01 - 2.39), than among men 
who had insurance and also used cash payment (aRR=1.84; 95% CI: 1.62 - 2.09), than 
among women who used insurance exclusively (aRR=1.03; 95% CI: 0.93 - 1.15). 
Excess relative risk due to interaction was 0.32 on the risk ratio scale which means 
there is a positive modification the association between cash payment and the risk of 
potential prescription opioid misuse on the additive scale. In both age groups, 
exclusive cash payment was associated with a much lower risk of potential 
prescription opioid misuse.  
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Conclusion: While there may be legitimate reasons to pay for opioid prescriptions in 
cash, this study suggests that patients on COT who pay for some, but not all, opioid 
prescriptions in cash should raise concern for potential opioid misuse only when the 
patient has other health insurance coverage. The public health and clinical 
implications of these findings warrant further study. 
INTRODUCTION 
The use of chronic opioid therapy (COT) for chronic non-cancer pain has increased 
tremendously over the last three decades despite lack of evidence for long-term 
effectiveness. There is evidence that excessive opioid prescribing has contributed to 
the current opioid epidemic since misuse of prescribed opioids has been associated 
with accidental opioid overdose-related deaths.1,2 The risk of prescription opioid 
misuse is the primary reason why almost all states now monitor the use of controlled 
substances using their prescription drug monitoring programs (PDMP). Validated 
criteria have been developed to help identify patterns of prescription opioid consistent 
with prescription opioid misuse among patients on chronic opioid therapy using 
administrative claims data.3  
Limited data suggest that information on the method of payment may help 
detect potential prescription opioid misuse and contribute to improved opioid 
prescribing among physicians by identifying patients at high-risk for overdose. Almost 
all state PDMPs collect information on method payment, and a recent study showed 
that the proportion of controlled substances paid for in cash varies by about 3-fold 
across states.4 High percentages of opioid prescriptions paid for in cash are generally 
regarded with suspicion because patients who seek prescriptions of the same 
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controlled substances from multiple prescribers are more likely to pay for their 
prescriptions in cash.5 Furthermore, the National Association of Boards of Pharmacy, 
PDMP administrators and law enforcement investigators believe that cash payment 
indicates potential prescription opioid misuse, especially when the patient has other 
health insurance coverage.6 “Pill mills” also accept cash payment as a way to avoid 
detection.7 The practice of concealing potential opioid misuse could have significant 
implications for drug utilization reviews since these evaluations are often restricted to 
specific health systems and could miss opioid prescriptions paid in cash. 
Understanding how cash payment relates to potential prescription opioid misuse may 
shed light on the public health magnitude of the problem and provide new ways to 
identify potential opioid misuse from a payer perspective.   
BACKGROUND 
Each year about twenty percent of adults in the United States are prescribed opioid 
analgesics for a variety of painful conditions ranging from acute pain due to injury to 
chronic cancer pain and pain occurring during terminal illness. Initial opioid therapy 
often intended by prescribers for short-term use sometimes leads to unintended long-
term use, with adverse health outcomes including opioid misuse, overdose, and 
opioid-related deaths.8-12 Prescription opioid misuse (POM) often precedes heroin 
use.13 The rise in POM has been associated with a corresponding increase in opioid 
prescribing for therapeutic uses especially among patients with chronic pain. A recent 
study of controlled substance prescribing patterns in eight US states found that opioid 
analgesics were prescribed twice as often as stimulants or benzodiazepines.4 A 
relatively small proportion of prescribers were responsible for a large proportion of 
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prescriptions. For example, overall 10% of prescribers accounted for more than 50% 
of opioid prescribing and in one state 25% of opioid prescription were prescribed by 1 
percent of prescribers. Prescription opioids for misuse are most commonly obtained 
from a family member or friend, but patients at highest risk of overdose are as likely to 
get them legally from a licensed clinician.13  
There is no universally accepted definition of prescription opioid misuse 
(POM). It may be broadly defined as any use of a prescription opioid medication 
without a prescription, or in ways that are not consistent with of the recommendations 
of the prescriber including excessive use (higher amounts, frequency or duration), 
deliberate use for euphoria, diversion for illicit use, or having multiple providers 
prescribing overlapping prescriptions of the same medication. In this study, we focus 
on the excessive use of prescription opioid analgesics legally obtained from a licensed 
provider and filled at a retail pharmacy. A recent systematic review of seven studies 
highlighted differences in the way researchers have conceptualized, operationalized, 
and conducted validation studies.14 Three of the studies considered POM in terms of 
potential or probable misuse of opioid medications acknowledging the difficulties in 
establishing a diagnosis of misuse from secondary sources. Several items have been 
used to develop algorithms to identify cases of POM including the use of ICD-9 codes, 
prescription records, pharmacy records, and urinary toxicology. Sullivan et al used the 
number of providers and pharmacies, and number of days’ supply to develop an 
algorithm that was validated using a quantitative criterion validity study in two types 
of administrative claims databases, including a commercial health plan and Medicaid, 
with adequate support for its use.3  
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According to a recent survey, the most common reason for POM among 
patients on opioids is to relieve physical pain suggesting that misuse most commonly 
occurs among patients on COT.15 Compared with opioid-naïve patients, the use of 
cash payment and POM behavior were more common among patients on COT, 
especially those taking schedule II opioids.5 Several risk factors have been associated 
with POM among patients on COT; these include being young or middle aged adults, 
white race, and a history of mental health disorders (including depression or 
posttraumatic stress disorder), and a family or personal history substance use disorder, 
including tobacco use.16-26 The risk of POM was the primary reason why states 
monitor controlled substances using PDMP and in recent years, there has been a 
growing interest in using PDMP data for epidemiologic and health services research 
despite absence important clinical and demographic variables.27 One of the unique 
features of most PDMP is their ability to capture almost all outpatient opioid 
prescriptions filled at a retail pharmacy with the method of payment used by the 
patient irrespective of their insurance coverage.  
The decision to pay for an opioid prescription with cash depends on many 
factors including promotional cheaper generic formulations, lack of health insurance 
or prescription drug coverage, the existence of a gap in prescription drug coverage 
especially among the elderly, or simply to minimize information made accessible to 
drug utilization reviewers.28 At least 47 states collect information on the method of 
payment including Rhode Island. Program administrators, law enforcement 
investigators, and some organizations believe that cash payment suggests POM, 
especially when the patient has other health insurance coverage.6,29 However, few 
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studies have attempted to evaluation this association because most claim data sources 
do not capture the method of payment including cash.30 The use of cash payment can 
have significant implications for drug utilization evaluation since these evaluations are 
often restricted to specific health systems which do not capture opioid prescriptions 
paid with cash. Understanding the relationship between cash payment and POM may 
provide policy-makers with another tool to design intervention focused on the 
populations most at risk of POM. The objective of this study was to evaluate the 
relationship between method of payment and potential POM among patients on 
chronic opioid therapy. 
METHODS 
Study design, data source, and study population: A cross-section study was 
conducted using the 2015 Rhode Island PDMP data, which contains de-identified 
records of controlled substances dispensed by all retail pharmacies in the state. These 
include a unique patient, prescriber, and dispensing pharmacy information, and a 
limited number of variables such as age (in years) and sex of the patient, National 
Drug Code numbers (NDC), product name, strength, formulation, and therapeutic 
class code of the drug, number of days’ supply, metric quantity dispensed, method of 
payment, and the date each prescription was filled. The method of payment field 
populated by the dispensing pharmacist as commercial was reclassified as Medicare if 
the patient was aged 65 years and older since they were more likely to be enrolled in a 
Medicare plan. The data does not include opioid prescriptions filled during in-patient 
admission, incarceration, or substance abuse treatment. A detailed description of the 
data has been published elsewhere.31  
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All patients who filled at least one opioid prescription at a RI retail pharmacy 
during 2015 calendar year were eligible for inclusion in the study, regardless of the 
indication for the opioid medication. Schedule II-IV opioid prescriptions filled 
between January 1, 2015 and December 31, 2015 were identified using the National 
Drug Code numbers. We excluded opioid medications used for OUD treatment,32 
compounded formulations and bulk containers (for which do not have patient-level 
data), prescriptions with improbable data, or patients with missing sex. The time 
between the first and the last opioid prescription during the year was required to be at 
least 180 days since we were interested in POM among patients on COT. Chronic 
opioid therapy was defined as receiving at least 90 non-overlapping days’ supply 
during a 6-month period.33  
Primary exposure and covariate information: Method of payment, the primary 
independent variable for the analysis, was categorized as no cash (if the patients used 
insurance exclusively), cash only, or both (if the patient had insurance and paid for at 
least one opioid prescription with cash). We converted opioid prescriptions dosing 
information to daily milligrams of morphine equivalent by multiplying the quantity of 
each prescription by the strength of the prescription and multiplying this total by the 
CDC 2015 conversion factor34. For patients who received more than one opioid 
prescription on any given day, milligrams MME of each prescription were added 
together. Age (in years), gender, type of opioid and other concurrent controlled 
substances were captured in the database. Age was categorized as < 44, 45-54, 55-64, 
and 65 and above. Since some patients filled more than one type of opioid prescription 
during the year, the type of opioid was defined as the most commonly filled 
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medication type, according to the number of dispensings during the year. To examine 
the concurrent use of benzodiazepines, each prescription’s dates of use were 
calculated from the fill date plus the number of days supplied. Any patient with at 
least 90 days of overlapping dates of both a benzodiazepine and an opioid prescription 
in a year were considered as chronic overlapping or concurrent therapy.  
Measurement of primary outcome: A modified validated opioid misuse index that 
combines the number of prescribers and pharmacies used, and days’ supply of short-
acting and long-acting opioids was used to define potential POM.3,35 The algorithm 
uses the frequencies of unique providers and pharmacies utilized and counts of days’ 
supply of long and short-acting opioids. Days supplied of short-acting opioids (91-
185, 186-240, >240 days) and long-acting opioids (91-185, 186-240, >240 days) 
during a 6-month period, and the number of opioid prescribers (≤2, 2-4, ≥5) and the 
number of pharmacies used (≤2, 2-4, ≥5) during the same time period are each 
assigned 0, 1, or 2 points, respectively. The total score for the six months was used to 
classify patients as ‘no misuse’ (score=0) or ‘possible misuse’ (score=1) and ‘probable 
misuse’ (score ≥2). To create a binary outcome variable, the last two categories were 
combined to form a category of ‘potential misuse’. 
Statistical analysis: Descriptive statistics were used to compare characteristics of 
patients grouped by method of payment. A risk factor model was constructed with 
significant potential confounders included in the model to evaluate the association 
between method of payment and potential POM. Since risk ratio were our parameters 
of interest, a multivariable binomial generalized linear model with a log link functions 
was used to estimate the adjusted risk ratios, controlling for sex, age group, type of 
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opioid prescription, and concurrent chronic benzodiazepine use.36,37 Because the 
pharmacy benefit design for many Medicare Part D drug plans includes a coverage 
gap where patients pay cash for a limited period of time, the analysis was stratified by 
age group (patients under 65 years versus patients 65 years and over). Since the 
association between method of payment and potential POM was modified by sex 
among patients 65 years and older, relative excess risk due to interaction (RERI) was 
used to assess departure from additivity of ‘effects’ on a relative risk and risk 
difference scales. All analyses were performed with SAS version 9.4 (SAS Institute, 
Cary, NC) and all tests of statistical significance were two-sided and performed at the 
alpha = 0.05 significance level. 
RESULTS 
A total of 45,332 patients met the inclusion criteria for COT, of which 80.3% paid for 
all of their opioid prescriptions with a third party insurance exclusively, 3.1% used 
only cash, and 16.6% had insurance coverage but paid for at least one opioid 
prescription with cash. Table 1 shows overall and group-specific patient 
characteristics. The mean age of patients was 56.8 years (standard deviation [SD] 
=16.3) and 59.1% were female. More than 30% of patients were aged 65 years and 
older. On average, patients who used cash exclusively were older than patients who 
had insurance but the difference in age was not statistically significant. More than 
55% of patients who used cash exclusively were aged 65 years and older. Patients who 
had insurance and paid for at least opioid prescription with cash were more likely to be 
in the age group 65 years and older than patients who used insurance exclusively for 
all opioid prescriptions (41.8% vs. 27.1%).  
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 Most patients used commercial insurance to pay for their opioid prescriptions.  
Among patients who had insurance and paid for at least opioid prescription in cash, 
36.7% had Medicare compared with 31.6% who also had commercial insurance. A 
higher proportion of patients who used cash exclusively filled fewer prescriptions and 
used a lower average daily MME compared with those who had insurance. The 
average number of opioid prescriptions among exclusive cash users was 7.82 
(SD=5.39) compared with 9.92 (SD = 7.47) and 13.37 (SD = 9.97) among those who 
used insurance only or both cash and insurance, respectively. The highest proportions 
of those who filled 11 or more prescriptions and utilized on average 90 or more MME 
per day was among patients with insurance coverage who paid for at least one opioid 
prescription in cash. Furthermore, patients using cash only tended to have one or two 
prescribers (78.5%) and visited only one or two pharmacies (96.1%) compared with 
those who had some insurance coverage. Almost 40% of patients who used cash and 
insurance had four or more prescribers. Similarly, the highest proportion of patients on 
concurrent chronic benzodiazepine use (18.0%) was among those who used cash and 
insurance to pay for opioid prescriptions.  
 Table 2 shows the results of the log-binomial regression modeling the 
relationship between method of prescription opioid payment and potential POM. A 
total of 10,015 patients (22.1%) were classified as having a pattern of opioid filling 
consistent with potential POM. Among patients under 65 years old on COT, those 
who had insurance coverage and paid for at least one of their opioid prescriptions in 
cash were 1.8 times more likely to exhibit a pattern of prescription opioid filling 
suggestive of POM as compared with those who paid for all their opioid prescriptions 
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with insurance exclusively, after controlling for potential confounding variables (RR= 
1.8; 95% CI: 1.73 - 1.87). After adjusting for age group, sex, type of opioid 
prescription, and concurrent chronic benzodiazepine use, the use of cash exclusively 
among patients younger than 65 years old reduced the risk of potential POM by 52% 
when compared to those who had insurance and used it exclusively to purchase their 
opioid prescriptions (RR= 0.48; 95% CI: 0.38 -  0.61).  
Among patients aged 65 years and older, the strength of the association 
between a dichotomous method of payment (insurance with at least one cash payment 
versus insurance exclusively) and potential POM differed by gender (p = 0.0174). The 
results of interaction analyses are summarized in Table 3 where men who used only 
third party insurance were used as the reference group for all comparisons. Compared 
with men who used only insurance to buy their opioid prescriptions, the risk of 
potential POM was higher among women who had insurance and used cash payment 
(aRR=2.19; 95% CI: 2.01 - 2.39), than among men who had insurance and also used 
cash payment (aRR=1.84; 95% CI: 1.62 - 2.09), than among women who used 
insurance exclusively (aRR=1.03; 95% CI: 0.93 - 1.15). After adjusting for age, sex, 
type of opioid medication, and concurrent benzodiazepine use, the relative excess risk 
due to interaction (RERI) was 0.32 on the additive and multiplicative scales. This 
indicates that on the additive scale, the excess relative risk of potential POM 
associated with being a woman aged 65 years and older with insurance who also uses 
cash payment is greater than the excess relative risk associated with female gender or 
using cash when the patient has insurance alone. On a multiplicative scale, the ratio of 
RRs in strata of the sex of 1.15 indicates that the estimated joint impact of both factors 
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(female sex and use of insurance with some cash purchase) together was 15% larger 
than the product of the relative risk associated with each factor acting alone. Among 
patients aged 65 and older, exclusive cash payment was associated with a 60% lower 
risk of potential POM among men (aRR=0.40; 95% CI: 0.24 - 0.69) compared with 
exclusive use of insurance payment; among women the risk reduction associated with 
exclusive cash use was not statistically significant, after adjusting for potential 
confounders (aRR=0.48; 95% CI: 0.15 - 1.56).  
DISCUSSION 
We found that cash payment is associated with potential POM only when the patient 
has health insurance with prescription coverage. Among patients aged 65 and older, 
the strength of the association differed by gender; it was stronger among women than 
men. This is particularly concerning because in recent years the rate of overdose 
deaths involving opioid analgesics among women is almost double that among 
males.38 Our findings are consistent with those of other studies and reports from 
several organizations including the Center for Disease Control and Prevention linking 
cash payment for controlled substances to potential opioid misuse.5,6,29,30 A recent 
cross-sectional study of individuals with Veterans Health Administration payment for 
prescription opioid analgesics in Kentucky found that additional sources of payment 
for opioids, especially cash, were associated with the receipt of risky opioid regimens 
defined as a combination of opioid/benzodiazepine therapy or high-dose (daily MME 
> 90mg) opioid therapy.39 Since a common reason for opioid misuse is persistent pain, 
it is likely that patients with health insurance pay for some prescriptions with cash 
because a refill for an opioid prescription requested too early would not be covered by 
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their insurance or if their coverage limit is exceeded. Among patients who had 
insurance and paid for some opioid prescriptions with cash, 36% were Medicare 
beneficiary, likely reflecting gaps in prescription drug coverage among patients with 
Medicare Part D.  
  There is limited evidence that patients who seek prescriptions of the same 
controlled substance from multiple prescribers are more likely to pay for their 
prescriptions in cash.5 We found that 17% of patients on long-term opioid therapy who 
had insurance coverage during the study year paid for at least one opioid prescription 
with cash.28 This group of patients was more likely to see multiple providers and 
pharmacies than patients who use only cash or insurance. In our study, 8.1% of opioid 
prescriptions among patients on COT were paid for in cash. This is similar to those of 
a recent study using PDMP data in which five states collected information on the 
method of payment and the proportion of prescription opioid analgesics paid for in 
cash varied about from 8% to 19.5%.4 In that study, a higher percentage of cash 
payment was seen in states with smaller proportions of Medicaid payment. This 
suggests that low Medicaid coverage may leave many people without insurance who 
left to pay for their opioid prescriptions with cash. Some studies have reported that 
providers profiteering usually accept only cash payment as a way to reduce the amount 
of information available to investigators to track and identify the patients and 
prescribers involved.7 In our study oxycodone, hydrocodone and tramadol were the 
most common opioid prescriptions paid with cash. According to the CDC, oxycodone 
and hydrocodone constitute two of the three most common drugs involved in 
prescription opioid overdose deaths in the United States. A recent study found that 
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hydromorphone, fentanyl, and methadone were more likely than other prescription 
opioid analgesics to be paid with cash.30 However, cash payment was defined in that 
study as an opioid prescription fill identified in a PDMP data set without a 
corresponding matching claim in a Medicaid pharmacy claim within a few days. Our 
analysis uses cash payment recorded at the time the opioid prescription was dispensed 
and is likely to provide a more accurate estimate of the association.   
 Patients who paid for all their opioid prescriptions with cash were older, filled 
fewer opioid prescriptions, had a lower average daily dose, and spent on average less 
on opioid prescriptions than patients who had insurance. Cash only opioid users also 
saw fewer prescribers and visited fewer pharmacies. Since our operational definition 
of potential POM was based on days’ supply (which is associated with the number of 
prescription) and number of prescribers and pharmacies, it is not surprising that use of 
cash only is associated with a lower risk of potential POM. In this sample, patients 
who used only cash probably lacked health insurance and could not afford to pay for 
expensive opioid prescriptions. Other studies have found that patients who misuse 
prescription opioids were more frequently uninsured, jobless, or low income adults.15 
The fact that a higher proportion of older patients paying for all opioid prescriptions 
with cash is surprising because almost all patients aged 65 years and older are on 
Medicare unless they do not have prescription drug coverage. On the contrary, patients 
who had health insurance with drug coverage, on average, filled more prescriptions at 
higher doses, saw more prescribers, visited more pharmacies, and spent more on 
opioid prescription (See Table 3 in Appendix C).  
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Estimates of the prevalence of POM among patients who are prescribed opioid 
analgesics vary tremendously, reflecting differences in the study populations and 
definitions of POM used. Twenty-two percent of patients on long-term opioid therapy 
on our study had a pattern of opioid filling consistent with potential POM. This is 
similar to other estimates of behaviors consistent with POM among patients on 
prescription opioids ranging from 16 to 78%.17,20,21 The 2015 National Survey on 
Drug Use and Health in the United States estimated that among the 92 million adults 
prescribed opioid medications the previous year, 13 % reported POM while a recent 
primary care study of over 6,000 United States veterans found a prevalence of 5%.15,26 
These studies and ours suggest that POM is a serious public health problem in the 
United States. Our study suggests that use of cash payment when a patient has other 
health insurance coverage may be a surrogate marker of potential POM.  
LIMITATIONS 
Our study has some limitations. First, being a cross sectional study we could only 
demonstrate associations between method of payment and potential POM, not 
causality. We assumed that our modified validated measure of opioid misuse correctly 
identified patients who actually misused opioids. However, we did not have any 
clinical documentation or patient reported opioid use to ascertain the way prescribed 
opioids were used. Multiple prescribers may be part of a coordinated care within a 
large group practice and thus not necessarily represent risk of opioid misuse. Second, 
we could not account for opioid prescriptions filled in neighboring states since the data 
source does not provide that information. In a recent study looking at potential misuse 
of medications used to treat attention deficit hyperactivity disorder, patients with 
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potential misuse behavior traveled longer distances and visited more states to fill their 
medications than patients without similar behaviors.40 It is estimated that about 20% of 
patients who misuse opioid prescriptions get their prescriptions filled in more than one 
state compared to only 4% of patients with no evidence of opioid misuse.41 Third, the 
method of payment may not have captured Medicare or Medicaid payment accurately. 
Reclassification of patients aged 65 years and older with commercial insurance as 
Medicare may have led to some misclassification of some methods of payment. 
However, such misclassification did not involve cash payment and therefore would 
not be expected to affect our results. Fourth, we lacked information on socioeconomic 
status, indications for opioid prescription, and use of illicit opioids. 
CONCLUSIONS 
Our study provides one of the first estimates of the relationship between cash payment 
and potential POM among patients on COT using a data source that directly captures 
the method of payment irrespective the patient’s health insurance. Seventy percent of 
patients with insurance having drug coverage paid for at least one opioid prescription 
with cash. While there may be legitimate reasons to pay for opioid prescriptions with 
cash, this study suggests that patients on COT who pay for some, but not all, opioid 
prescriptions in cash should raise special concerns for potential opioid misuse only 
when the patient has other health insurance with drug coverage. Among patients aged 
65 years and older, the strength of the association between cash payment and potential 
POM is stronger among women than men. Further research is needed to determine the 
public health relevance of these findings and whether cash payment is associated with 
adverse health outcomes. 
 
85 
 
REFERENCES 
1. Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes 
and Likelihood of Long-Term Opioid Use - United States, 2006-2015. MMWR. 
Morbidity and mortality weekly report. Mar 17 2017;66(10):265-269. 
2. Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After 
Minor and Major Surgical Procedures in US Adults. JAMA surgery. Jun 21 
2017;152(6):e170504. 
3. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. 
Risks for possible and probable opioid misuse among recipients of chronic opioid 
therapy in commercial and medicaid insurance plans: The TROUP Study. Pain. Aug 
2010;150(2):332-339. 
4. Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM, Centers for Disease C, 
Prevention. Controlled Substance Prescribing Patterns--Prescription Behavior 
Surveillance System, Eight States, 2013. Morbidity and mortality weekly report. 
Surveillance summaries. Oct 16 2015;64(9):1-14. 
5. Cepeda MS, Fife D, Chow W, Mastrogiovanni G, Henderson SC. Opioid 
shopping behavior: how often, how soon, which drugs, and what payment method. 
Journal of clinical pharmacology. Jan 2013;53(1):112-117. 
6. NABP. Stakeholders' challenges and red flag warning signs related to 
prescribing and dispensing controlled substances 2015. 
7. Rigg KK, March SJ, Inciardi JA. Prescription Drug Abuse & Diversion: Role 
of the Pain Clinic. Journal of drug issues. 2010;40(3):681-702. 
 
86 
 
8. Waljee JF, Li L, Brummett CM, Englesbe MJ. Iatrogenic Opioid Dependence 
in the United States: Are Surgeons the Gatekeepers? Annals of Surgery. 
2017;265(4):728-730. 
9. Callinan CE, Neuman MD, Lacy KE, Gabison C, Ashburn MA. The Initiation 
of Chronic Opioids: A Survey of Chronic Pain Patients. The Journal of 
Pain.18(4):360-365. 
10. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The 
role of opioid prescription in incident opioid abuse and dependence among individuals 
with chronic noncancer pain: the role of opioid prescription. The Clinical journal of 
pain. Jul 2014;30(7):557-564. 
11. Stumbo SP, Yarborough BJ, McCarty D, Weisner C, Green CA. Patient-
reported pathways to opioid use disorders and pain-related barriers to treatment 
engagement. Journal of substance abuse treatment. Feb 2017;73:47-54. 
12. Deyo RA, Hallvik SE, Hildebran C, et al. Association Between Initial Opioid 
Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naive Patients: 
A Statewide Retrospective Cohort Study. Journal of general internal medicine. Aug 2 
2016. 
13. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users 
of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug 
and alcohol dependence. Sep 1 2013;132(1-2):95-100. 
14. Cochran G, Woo B, Lo-Ciganic WH, Gordon AJ, Donohue JM, Gellad WF. 
Defining Nonmedical Use of Prescription Opioids Within Health Care Claims: A 
Systematic Review. Subst Abus. 2015;36(2):192-202. 
 
87 
 
15. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription 
opioid use, misuse, and use disorders in u.s. adults: 2015 national survey on drug use 
and health. Annals of internal medicine. 2017;167(5):293-301. 
16. Kaye AD, Jones MR, Kaye AM, et al. Prescription Opioid Abuse in Chronic 
Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid 
Abuse: Part 1. Pain physician. Feb 2017;20(2S):S93-S109. 
17. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use 
disorders in a primary care sample receiving daily opioid therapy. The journal of pain 
: official journal of the American Pain Society. Jul 2007;8(7):573-582. 
18. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid 
misuse in patients with chronic pain: a prospective cohort study. BMC health services 
research. Apr 4 2006;6:46. 
19. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O'Connor 
PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. 
Journal of general internal medicine. Mar 2002;17(3):173-179. 
20. Morasco BJ, Dobscha SK. Prescription medication misuse and substance use 
disorder in VA primary care patients with chronic pain. General hospital psychiatry. 
Mar-Apr 2008;30(2):93-99. 
21. Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in 
patients treated for chronic pain: importance of abuse history. Journal of pain and 
symptom management. Sep 2004;28(3):250-258. 
22. Liebschutz JM, Saitz R, Weiss RD, et al. Clinical factors associated with 
prescription drug use disorder in urban primary care patients with chronic pain. The 
 
88 
 
journal of pain : official journal of the American Pain Society. Nov 
2010;11(11):1047-1055. 
23. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. 
Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related 
behavior among patients with chronic pain. The Clinical journal of pain. May 
2007;23(4):307-315. 
24. Becker WC, Starrels JL, Heo M, Li X, Weiner MG, Turner BJ. Racial 
differences in primary care opioid risk reduction strategies. Annals of family medicine. 
May-Jun 2011;9(3):219-225. 
25. Vijayaraghavan M, Penko J, Guzman D, Miaskowski C, Kushel MB. Primary 
care providers' judgments of opioid analgesic misuse in a community-based cohort of 
HIV-infected indigent adults. Journal of general internal medicine. Apr 
2011;26(4):412-418. 
26. Chabal C, Erjavec MK, Jacobson L, Mariano A, Chaney E. Prescription opiate 
abuse in chronic pain patients: clinical criteria, incidence, and predictors. The Clinical 
journal of pain. Jun 1997;13(2):150-155. 
27. O'Kane N, Hallvik SE, Marino M, et al. Preparing a prescription drug 
monitoring program data set for research purposes. Pharmacoepidemiology and drug 
safety. Sep 2016;25(9):993-997. 
28. Roberts AW, Farley JF, Holmes GM, et al. Controlled Substance Lock-In 
Programs: Examining An Unintended Consequence Of A Prescription Drug Abuse 
Policy. Health affairs. Oct 1 2016;35(10):1884-1892. 
 
89 
 
29. CDC. Pharmacists: on the front lines addressing prescription opioid abuse and 
overdose. Atlanta, GA: Center for Disease Control and Prevention; 2016. 
30. Hartung DM, Ahmed SM, Middleton L, et al. Using prescription monitoring 
program data to characterize out-of-pocket payments for opioid prescriptions in a state 
Medicaid program. Pharmacoepidemiology and drug safety. Sep 2017;26(9):1053-
1060. 
31. Aroke H, Buchanan A, Wen X, Ragosta P, Koziol J, Kogut S. Estimating the 
Direct Costs of Outpatient Opioid Prescriptions: A Retrospective Analysis of Data 
from the Rhode Island Prescription Drug Monitoring Program. Journal of managed 
care & specialty pharmacy. Mar 2018;24(3):214-224. 
32. Clemans-Cope L EM, Kenney GM. Rapid growth in medicaid 
spending on medications to treat opioid use disorder and overdose. Washington, DC: 
Urban Institute Health Policy Center;2017. 
33. Paulozzi LJ, Zhang K, Jones CM, Mack KA. Risk of adverse health outcomes 
with increasing duration and regularity of opioid therapy. Journal of the American 
Board of Family Medicine : JABFM. May-Jun 2014;27(3):329-338. 
34. CDC. National Center for Injury Prevention and Control. CDC compilation of 
benzodiazepines, muscle relaxants, stimulants, zolpidem, and opioid analgesics with 
oral morphine milligram equivalent conversion factors, 2015 version. . 2015; 
http://www.pdmpassist.org/pdf/BJA_performance_measure_aid_MME_conversion.pd
f. 
 
90 
 
35. Knisely JS, Wunsch MJ, Cropsey KL, Campbell ED. Prescription Opioid 
Misuse Index: a brief questionnaire to assess misuse. Journal of substance abuse 
treatment. Dec 2008;35(4):380-386. 
36. Spiegelman D, Hertzmark E. Easy SAS Calculations for Risk or Prevalence 
Ratios and Differences. American journal of epidemiology. 2005;162(3):199-200. 
37. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk 
differences. American journal of epidemiology. Jan 1986;123(1):174-184. 
38. (OWH) OoWsH. Final Report: Opioid Use, Misuse, and Overdose in Women. 
2017; https://www.womenshealth.gov/files/documents/final-report-opioid-508.pdf. 
39. Becker WC, Fenton BT, Brandt CA, et al. Multiple Sources of Prescription 
Payment and Risky Opioid Therapy Among Veterans. Medical care. Jul 2017;55 
Suppl 7 Suppl 1:S33-S36. 
40. Cepeda MS, Fife D, Berwaerts J, Friedman A, Yuan Y, Mastrogiovanni G. 
Doctor shopping for medications used in the treatment of attention deficit 
hyperactivity disorder: shoppers often pay in cash and cross state lines. The American 
journal of drug and alcohol abuse. May 2015;41(3):226-229. 
41. Cepeda MS, Fife D, Yuan Y, Mastrogiovanni G. Distance traveled and 
frequency of interstate opioid dispensing in opioid shoppers and nonshoppers. The 
journal of pain : official journal of the American Pain Society. Oct 2013;14(10):1158-
1161. 
 
 
 
 
91 
 
Table 1 Characteristics of patients on chronic opioid therapy by payment source in Rhode 
Island Prescription Drug Monitoring Program, 2015 
Characteristic  Overall 
(N=45,332) 
Cash only 
(N= 1,401) 
Insurance only 
(N= 36,409) 
Both 
(N=7,522) 
Continuous variables, mean (SD) 
Number of Rx 
Average cost ($) 
Average total cost ($) 
Age (years) 
 
  10.43 (7.910 
  54.50 (138.18) 
868.19 (2955.84) 
  56.80 (16.29) 
 
    7.82 (5.39) 
  27.17 (55.35) 
302.05 (949.22) 
  61.74 (21.07) 
 
    9.92 (7.47) 
  56.18 (145.17 
867.59 (3036.31) 
  55.98 (15.74) 
 
  13.37 (9.97) 
  51.46 (111.00) 
976.55 (2791.45) 
  59.83 (17.30) 
Age group (years) 
< 44  
45-54  
55-64  
65+ 
 
  9,897 (21.83) 
  9,835 (21.70) 
11,822 (26.08) 
13,778 (30.39) 
 
250 (17.84) 
154 (10.99) 
224 (15.99) 
773 (55.17) 
 
  8,154 (22.40) 
  8,365 (22.98) 
10,030 (27.55) 
  9,860 (27.08) 
 
1,493 (19.85) 
1,316 (17.50) 
1,568 (20.85) 
3,145 (41.81) 
Gender 
Female 
Male 
 
26,799 (59.12) 
18,533 (40.88) 
 
776 (55.39) 
625 (44.61) 
 
21,606 (59.34) 
14,803 (40.66) 
 
4,417 (58.72) 
 3,105 (41.28) 
Primary method of payment 
Cash 
Medicaid  
Medicare  
Commercial Ins. 
Other 
 
  2,891 (6.38) 
  3,404 (7.51) 
15,635 (34.49) 
22,598 (49.85) 
     804 (1.77) 
 
1,401 (100.0) 
NA 
NA 
NA 
NA 
 
NA 
  2,675 (7.35) 
12,873 (35.36) 
20,223 (55.54) 
     638 (1.75) 
1,490 (19.81) 
   729 (9.69) 
2,762 (36.72) 
2,375 (31.57) 
   166 (2.21) 
Primary opioid type used 
Hydrocodone  
Oxycodone  
Tramadol  
Other  
 
15,347 (33.85) 
15,577 (34.36) 
  8,795 (19.40) 
  5,613 (12.38) 
 
356 (25.41) 
313 (22.34) 
568 (40.54) 
164 (11.71) 
 
12,881 (35.38) 
12,188 (33.48) 
  6,802 (18.68) 
  4,538 (12.46) 
 
2,110 (28.05) 
3,076 (40.89) 
1,425 (18.94) 
   911 (12.11) 
Number of opioid dispensing 
≤ 5 
6-10 
11+ 
 
14,366 (31.69) 
10,894 (24.03) 
20,072 (44.28) 
 
593 (42.33) 
389 (27.77) 
419 (29.91) 
 
12,181 (33.46) 
  8,741 (24.01) 
15,487 (42.54) 
 
1,592 (21.16) 
1,764 (23.45) 
4,166 (55.38) 
Average daily MME 
≤ 50 
50-90 
90+ 
 
35,370 (78.02) 
  6,482 (14.30) 
  3,480 (7.68) 
 
1,246 (88.94) 
   106 (7.57) 
     49 (3.50) 
 
28,728 (78.90) 
  5,007 (13.75) 
  2,674 (7.34) 
 
5,396 (71.74) 
1,369 (18.20) 
   757 (10.06) 
Number of opioid prescribers  
1 
2 
3 
4+ 
 
13,021 (28.72) 
13,550 (29.89) 
  8,394 (18.52) 
10,367 (22.87) 
 
667 (47.61) 
433 (30.91) 
173 (12.35) 
128 (9.14) 
 
11,087 (30.45) 
11,305 (31.05) 
6,755 (18.55) 
7,262 (19.95) 
 
1,267 (16.84) 
1,812 (24.09) 
1,466 (19.49) 
2,977 (39.58) 
Number of  Pharmacies visited 
1 
2 
3 
4+ 
 
27,292 (60.20) 
12,024 (26.52) 
  3,846 (8.48) 
  2,170 (4.79) 
 
1,102 (78.66) 
   244 (17.42) 
     44 (3.14) 
     11 (0.79) 
 
23,247 (63.85) 
  9,044 (24.84) 
  2,738 (7.52) 
  1,380 (3.79) 
 
2,943 (39.13) 
2,736 (36.37) 
1,064 (14.15) 
   779 (10.36) 
Concurrent benzodiazepines 
No 
Yes 
 
38,053 (83.94) 
  7,279 (16.06) 
 
1,241 (88.58) 
   160 (11.42) 
 
30,641 (84.16) 
  5,768 (15.84) 
 
6,171 (82.04) 
1,351 (17.96) 
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Table 2 Multivariable log binomial regression models of the association between  
method of payment and potential POM among patients younger than 65 years  
old on chronic opioid therapy 
Characteristic  Unadjusted RR (95% CI) Adjusted RR (95% CI) 
Method of payment  
Insurance only 
Cash only 
Both 
 
Ref. 
0.44 (0.34, 0.56) 
2.04 (1.95, 2.12) 
 
Ref. 
0.48 (0.38, 0.61) 
1.80 (1.73, 1.87) 
Age group (years) 
< 44  
45-54  
55-64 
 
Ref. 
1.12 (1.07, 1.18) 
0.97 (0.93, 1.02) 
 
Ref. 
1.07 (1.02, 1.12) 
0.96 (0.91, 1.00) 
Gender 
Male 
Female 
 
Ref. 
1.01 (0.97, 1.05) 
 
Ref. 
1.01 (0.97, 1.05) 
Primary opioid type  
Hydrocodone  
Oxycodone  
Tramadol  
Other 
 
Ref. 
1.86 (1.78, 1.95) 
0.86 (0.80, 0.93) 
1.50 (1.40, 1.60) 
 
Ref. 
1.73 (1.65, 1.81) 
0.86 (0.80, 0.93) 
1.46 (1.37, 1.56) 
Overlapping benzodiazepine 
No 
Yes 
 
Ref. 
1.91 (1.84, 1.99) 
 
Ref.  
1.74 (1.67, 1.81) 
 
 
Table 3 Modification of the association between methods of payment and potential opioid misuse 
by gender among patients 65 years and older on chronic opioid therapy using the risk ratio scale 
 Insurance exclusively Insurance and ≥ 1 cash payment RRs (95% CI) for payment 
method within strata of 
gender 
 N with/without POM RR (95% CI) N with/without POM RR (95% CI) 
Male 478/3038   1.0 287/799 (35.9) 1.84 (1.62, 2.09) 
p < 0.0001 
1.84 (1.62, 2.09) 
p < 0.0001 
Female 864/5480  1.03 (0.93, 1.15) 
p=0.1295 
656/1403 (46.8) 2.19 (2.01, 2.39) 
p < 0.0001 
2.12 (1.98, 2.27) 
p < 0.0001 
Measure of association modification on additive scale: RERI = 0.32; p < 0.0001 
Measure of association modification on multiplicative scale: Ratio of RRs =1.15 (95% CI: 1.08–1.22). 
RRs were adjusted for age, sex type of opioid medication, and chronic concurrent benzodiazepine use. 
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Figure 1. Flow chart for study cohort selection 
 
 
Schedule II-IV opioids prescriptions 
N = 222,513 (809,195 Rx) 
After excluding bulk agents 
N = 222,464 (764,113 rx) 
After excluding MAT 
N = 216982 (760,071 rx) 
After excluding patients with only one prescription 
N = 97,507 (640,596 rx) 
At least 180 days between first and last prescription 
N = 45,333 (472,739 rx) 
After excluding one patient with missing sex 
N = 45,332 (472,737 rx) 
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CHAPTER 4 
 
FUTURE RESEARCH WORK 
In the first manuscript, we used a baseline model to evaluate the association of the 
initial pattern of prescription opioid use on the risk of all-cause mortality. We plan to 
perform additional analysis with time-varying exposure and time-varying confounding 
using marginal structural models. Prescription opioids use tends to vary over time and 
standard approaches for adjustment of confounding discussed here can be biased in the 
presence of time-dependent confounders that are also affected by previous prescription 
opioid exposure. In a situation like the one just described, marginal structural models 
may allow for improved adjustment of confounding. 
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APPENDICES 
Appendix A 
Table 1. Current Procedural Terminology (CPT) and International Classification of Diseases, Ninth Revision (ICD-9) 
codes for surgical procedures 
Surgical procedures CPT codes 
Total Knee Arthroplasty  
Total Hip Arthroplasty 
Laparoscopic Cholecystectomy  
Open Cholecystectomy 
Laparoscopic Appendectomy 
Open Appendectomy 
Cesarean Section 
FESS 
Cataract Surgery 
TURP 
Simple Mastectomy 
Carpal tunnel release 
Parathyroidectomy  
Varicose veins 
Hemorrhoidectomy  
Thyroidectomy 
27447 
27130 
47562, 47563, 47564 
47600, 47605, 47610 
44970, 44979 
44950, 44960 
59510, 59514, 59515 
31237, 31240, 31254, 31255, 31256, 31267, 31276, 31287, 31288 
66982, 66983, 66984 
52601, 52612, 52614, 52480,52630 
19301, 19302, 19303, 19180 
64721 
60500 
37785 
46221, 46945, 46946, 46250, 46260, 46257, 46258, 46261, 46262,46255 
60240 
Surgical procedures ICD-9codes 
Gastric procedures 
Incisional hernia repair 
Esophagus  
Diaphragm  
Colon  
Uterus 
4498,4464,4495, 4438,4468,4382,4439 
5351,5362,5359 
4495,4466 
5362,5371, 5383,5372,5361,5384,5369, 5363,5375,5380 
4581, 4573, 4582, 4583 
6831,6841, 6851, 6839,6849,689 
FESS=Functional endoscopic sinus surgery, TURP=transurethral resection of the prostate
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Table 2. Pain diagnoses 
Pain disorder category ICD-9 codes 
Headache/migraines '3840', '3502', '34000', '346', '3460',  '3461',  '3462',  '3463', '3464', '3465',  '3466', '3467' , '3468',  '34600', '34601', '34602', '34603', 
'34610', '34611', '34612', '34613', '34620', '34621', '34622', '34623', '34630', '34631', '34632', '34633', '34640', '34641', '34642', 
'34643', '34650', '34651', '34652', '34653', '34660', '34661', '34662', '34663', '34670', '34671', '34672', '34673', '34680', '34681', 
'34682', '34683', '34690', '34691', '34692', '34693', '30781', '7840','7238','3469' 
Neck/TMJD '72231','72271','72281','72291','8390','8391','8470', '7210','7211','7220','723', '52460', '52461', '52462', '52463', '52464', '52469' 
Back '72230', '72232', '72233', '72270', '72272', '72273','72280', '72282', '72283', '72290', '72292', '72293','7371', '7373', '7384', '7385', 
'7392', '7393', '7394','75610', '75611', '75612', '75619', '8054', '8058', '8392', '83942', '846', '8460', '8471',  
'8472', '8473','8479', '75613', '7222' '724', '7213' - '7219' 
Abdominal pain  '7890' '78900' '78901' '78902' '78903' '78904' '78905' '78906' '78907' '78909' '78960' '78961' '78962' '78963' '78964' '78965' 
'78966' '78967' '78969' '5920' '5921' '5929' '5940' '5941' '5942' '5948' '5949' '7880' 'V1301' 
Joint/arthritis pain '710', '7101', '7103', '7104','734','725','7105', '7108', '7109', '729', '7292', '7294', '7295', '7296', '737', '7378', '7379', '738', '7382', 
'7383','7386', '7387', '7388', '7389', '739', '7391', '7395', '7396', '7397', '7398', '7399', '711', '712', '713', '714','715','716', '717', 
'718', '719','726', '727', '728', '7293','7297', '7298', '7299', '730','731', '732','733', '735', '736', '7372','7374', '7381' 
Fibromyalgia/CFS '7291','78071' 
Chronic pain syndrome '3380','3382','3384','339','346','30781','7840','805','806','846','847','3502','3540','3544','3555','35571','377',  '3370' -  '33719', '356' 
- '357',  '710' - '719',  '720' -  '724',  '725 - '729', '731' -  '738'  
Other pain conditions '78659', '5305','5368','7102','3883', '5951', '564','6257','617' 
TMJD=Temporal-mandibular joint disorder, CFS=Chronic fatigue syndrome, CPS=chronic pain syndrome; 
ICD-9= International Classification of Diseases, Ninth Revision code
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Table 3. Fractures and Strains 
Pain disorder category ICD-9 codes 
Fractures and strains '81000' '81001' '81002' '81003' '81010' '81011' '81012' '81013' '81100' '81101' '81102' '81103' '81109' '81110' '81111' '81112' 
'81113' '81119' '81200' '81201' '81202' '81203' '81209' '81210' '81211' '81212' '81213' '81219' '81220' '81221'  '81230' '81231' 
'81240' '81241' '81242' '81243' '81244' '81249' '81250' '81251' '81252' '81253' '81254' '81259' '81300' '81301' '81302' '81303' 
'81304' '81305'  '81306' '81307' '81308' '81310' '81311' '81312' '81313' '81314' '81315' '81316' '81317' '81318' '81320' '81321' 
'81322' '81323' '81330' '81331' '81332' '81333' '81340' '81341' '81342' '81343' '81344' '81345' '81346' '81347' '81350' '81351' 
'81352' '81353' '81354' '81380' '81381' '81382' '81383' '81390' '81391' '81392'  '81393' '81400' '81401' '81402' '81403' '81404' 
'81405' '81406' '81407' '81408' '81409' '81410' '81411' '81412' '81413' '81414' '81415' '81416' '81417' '81418'  '81419' '81500' 
'81501' '81502' '81503' '81504' '81509' '81510' '81511' '81512' '81513' '81514' '81519' '81600' '81601' '81602' '81603' '81610' 
'81611' '81612'  '81613' '8170' '8171'  '8180'  '8181'  '8190'  '8191'  '9052' '82100' '82101' '82110' '82111' '82120' '82121' '82122' 
'82123' '82129' '82130' '82131'  '82132' '82133' '82139' '8220'  '8221'  '82300' '82301' '82302' '82310' '82311' '82312' '82320' 
'82321' '82322' '82330' '82331' '82332' '82340' '82341'  '82342' '82380' '82381' '82382' '82390' '82391' '82392' '8240'  '8241'  '8242' 
'8243'  '8244'  '8245' '8246'  '8247'  '8248'  '8249'  '8250'  '8251'  '82520' '82521'  '82522' '82523' '82524' '82525' '82529' '82530' 
'82531' '82532' '82533'  '82534' '82535' '82539' '8260'  '8261'  '8270'  '8271'  '9054'  '80500' '80501' '80502' '80503' '80504' '80505' 
'80506' '80507' '80508' '80510'  '80511' '80512' '80513' '80514' '80515' '80516' '80517' '80518' '8052'  '8053' '8054'  '8055'  '8056'  
'8057'  '8058'  '8059'  '80700' '80701' '80702' '80703' '80704' '80705' '80706' '80707' '80708' '80709' '80710' '80711' '80712' '80713'   
'80714' '80715' '80716' '80717' '80718' '80719' '8072'  '8073'  '8074'  '8075' '8076' '8080'  '8081'  '8082'  '8083'  '80841' '80842' 
'80843' '80844' '80849' '80851' '80852' '80853' '80854' '80859' '8088'  '8089' '8090'  '8091'  '8280' '8281' '8290'  '8291'  '9051'  
'9055' '8400'  '8401'  '802'   '8403'  '8404'  '8405'  '8406'   '8407'  '8408'  '8409' '8410' '8411' '8412'  '8413'  '8418'  '8419'  '84200' 
'84201' '84202' '84209' '84210' '84211' '84212' '84213' '84219' '8430'  '8431'  '8438'  '8439'  '8440' '8441'   '8442'  '8443'  '8448'  
'8449'  '84500' '84501' '84502' '84503' '84509'  '84510' '84511' '84512' '84513' '84519' '8460'  '8461'  '8462'  '8463'  '8468' '8469' 
'8470'  '8471'  '8472'  '8473'  '8474'  '8479'  '8480'  '8481'  '8482' '8483'  '84840' '84841' '84842' '84849' '8485'  '8488'  '8489'  '9057'  
'V5414' 'V5415' 'V5416' 'V5424' 'V5425' 'V5426' 'V5410' 'V5411' 'V5412' 'V5420' 'V5421' 'V5422'  'V5417' 'V5419' 'V5427' 'V5429' 
'V664' 'V674' 'V1352' 'V540' 'V5401' 'V5402' 'V5409' '82000' '82001' '82002''82003' '82009' '82010' '82011' '82012' '82013' '82019' 
'82020' '82021' '82022' '82030' '82031' '82032' '8208'  '8209' '9053''V5413' 'V5423' '80000' '80001' '80002' '80003' '80004' '80005' 
'80006' '80009' '80050' '80051' '80052' '80053' '80054' '80055' '80056' '80059' '80100' '80101' '80102' '80103' '80104' '80105' 
'80106' '80109' '80150' '80151' '80152' '80153' '80154' '80155'  '80226' '80227' '80228' '80229' '80230' '80231' '80232' '80233' 
'80234' '80235' '80300' '80301' '80302' '80303' '80304' '80305' '80306' '80309' '80350' '80351'  '80352' '80353' '80354' '80355' 
'80356' '80359' '80400' '80401' '80402' '80403'  '80404' '80405' '80406' '80409' '80450' '80451' '80452' '80453' '80454' '80455'  
'80456' '80459' '9050' '80236' '80237' '80238' '80239' '8024' '8025' '8026' '8027' '8028' '8029' '80156' '80159' '8020' '8021' '80220' 
'80221' '80222' '80223' '80224' '80225' '34939' '80600' '80601' '80602' '80603' '80604' '80605' '80606' '80607' '80618' '80608' 
'80609' '80610' '80611' '80612' '80613' '80614' '80615' '80616' '80617'  '80619' '80620' '80621' '80622' '80623' '80624' '80625' 
'80626' '80627' '80628' '80629' '80630' '80631' '80632' '80633' '80634' '80635' '80636' '80637' '80638''80639' '8064' '8065' '80660' 
'80661' '80662' '80669' '80670' '80671' '80672' '80679' '8068' '8069' '9072' '95200' '95201' '95202' '95203' '95204' '95205''95206' 
'95207' '95208' '95209' '95210' '95211' '95212' '95213' '95214' '95215' '95216' '95217' '95218' '95219' '9522' '9523' '9524'  
'9528' '9529' 
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Table 4. Mental health disorders 
Mental health 
condition 
CCS  
codes 
ICD-9 
Adjustment disorders 650  3090 3091 30922 30923 30924 30928 30929 3093 3094 30982 30983 30989 3099               
Anxiety disorders 651 29384 30000 30001 30002 30009 30010 30020 30021 30022 30023 30029 3003 3005 30089 3009 3080 3081 3082 3083 3084 3089 30981 3130 3131 
31321 31322 3133 31382 31383                       
Conduct disorders 652 31200 31201 31202 31203 31210 31211 31212 31213 31220 31221 31222 31223 3124 3128 31281 31282 31289 3129 31381 31400 31401 3141 
3142 3148 3149                               
Mood disorders 657 29383 29600 29601 29602 29603 29604 29605 29606 29610 29611 29612 29613 29614 29615 29616 29620 29621 29622 29623 29624      29625 29626 
29630 29631 29632 29633 29634 29635 29636 29640 29641 29642 29643 29644 29645 29646 29650 29651 29652 29653 29654 29655 29656 29660 
29661 29662 29663 29664 29665 29666 2967 29680 29681 29682 29689 29690 29699 3004 311   
Schizophrenia &  
psychotic disorders 
659 29381 29382 29500 29501 29502 29503 29504 29505 29510 29511 29512 29513 29514 29515 29520 29521 29522 29523 29524 29525 29530 29531 
29532 29533 29534 29535 29540 29541 29542 29543 29544 29545 29550 29551 29552 29553 29554 29555 29560 29561 29562 29563 29564 29565 
29570 29571 29572 29573 29574 29575 29580 29581 29582 29583 29584 29585 29590 29591 29592 29593  29594 29595 2970 2971 2972 2973 2978 
2979 2980 2981 2982 2983 2984 2988 2989           
Alcohol related  
disorders 
660 2910 2911 2912 2913 2914 2915 2918 29181 29182 29189 2919 30300 30301 30302 30303 30390 30391 30392 30393 30500 
     30501 30502 30503 3575 4255 5353 53530 53531 5710 5711 5712 5713 76071 9800             
Substance related  
disorders 
661 2920 29211 29212 2922 29281 29282 29283 29284 29285 29289 2929 30400 30401 30402 30403 30410 30411 30412 30413 30420 
30421 30422 30423 30430 30431 30432 30433 30440 30441 30442 30443 30450 30451 30452 30453 30460 30461 30462 30463 30470 
30471 30472 30473 30480 30481 30482 30483 30490 30491 30492 30493 30520 30521 30522 30523 30530 30531 30532 30533 30540 
30541 30542 30543 30550 30551 30552 30553 30560 30561 30562 30563 30570 30571 30572 30573 30580 30581 30582 30583 30590 
30591 30592 30593 64830 64831 64832 64833 64834 65550 65551 65553 76072 76073 76075 7795 96500 96501 96502 96509 V6542 
Miscellaneous  
mental health  
disorders 
656, 
658, 
662, 
670 
31230 31231 31232 31233 31234 31235 31239 3010 30110 30111 30112 30113 30120 30121 30122 3013 3014 30150 30151 30159 3016 3017 30181 
30182 30183 30184 30189 3019 E9500 E9501 E9502 E9503 E9504 E9505 E9506 E9507 E9508 E9509 E9510 E9511 E9518 E9520 E9521 E9528 E9529 
E9530 E9531 E9538 E9539 E954 E9550 E9551 E9552 E9553 E9554 E9555 E9556 E9557 E9559 E956 E9570 E9571 E9572 E9579 E9580 E9581 E9582 
E9583 E9584 E9585 E9586 E9587 E9588 E9589 E959 V6284 29389 2939 30011 30012 30013 30014 30015 30016 30019 3006 3007 30081 30082 3021 
3022 3023 3024 30250 30251 30252 30253 3026 30270 30271 30272 30273 30274 30275 30276 30279 30281 30282 30283 30284 30285 30289 3029  
3060 3061 3062 3063 3064 30650 30651 30652 30653 30659 3066 3067 3068 3069 3071 30740 30741 30742 30743 30744 30745 30746 30747 30748 
30749 30750 30751 30752 30753 30754 30759 30780 30781 30789 3101 316 64840 64841 64842 64843 64844 V402 V403 V4031 V4039 V409 V673                                 
CCS=Clinical classification system code, ICD-9=International Classification of Diseases, Ninth Revision codes 
Source: Clinical Classification Software-DIAGNOSES (January 1980 through September 2015); Revised 03/24/2016 
https://www.hcup-us.ahrq.gov/toolssoftware/ccs/AppendixASingleDX.txt Accessed on 1/12/2018 
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Table 5.  List of Medical Comorbidities and ICD-9 Codes used 
Condition  ICD-9 codes 
Congestive Heart Failure '39891','4254','4255','4257','4258','4259','428' 
Myocardial infarction  '410' '412' 
Peripheral Vascular Disease  '0930','440','441','7854','V434', '4420'-'4428', '4431'-'4439', '44770'-
'44773' 
Chronic Obstructive  Pulmonary Disease
  
'4168','4169','5064','5191', '490' - '496', '500' - '505' 
Diabetes Mellitus  '250  ', '2500' - '2503' 
Diabetes Mellitus  with complications '3620', '2504', '2509' 
Chronic Kidney Disease  '40301','40311','40391','40402','40403','40412','40413','40492','40493
', '582', 
'583','585','586','588','V420','V451','V56' 
Cardiovascular disease '430' - '438' 
Dementia  '290','2910','2911','2912','29282','2941','3310','3311','3312','33182' 
Liver Disease  '07022','07023','07044','V427', '4560' - '4562', '5722' - '5728 
Cirrhosis  '07032','07033','07054','5712','5714','5715','5716' 
Ulcers  '531' - '534' 
Rheumatoid arthritis  '7100','7101','7104','71481','725  ', ('7140' - '7142' 
Paralysis '342','3449', '3440' – ‘3446' 
AIDS '79571','V08', '042' - '044' 
 
 
 
 
Table 6. Substance use disorders 
Diagnoses ICD-9 and ICD-10 codes 
Drug abuse '3040' '3041' '3046' '3046' '3047' '3048' '3049' '3054' '3055' '3058' 'F1120' 'F1121' 
'F1320' 'F1321' 'F1920' 'F1921' 'F1310' 'F1110' 'F1910' 
Overdose '9658' '9659' '967' '9691' '9692' '9693' '9694' '9695' '9697' '9698' '9699' '9752' '9753' 
'9778' '9779' 'T400X1A' 'T400X2A' 'T400X3A' 'T400X4A' 'T403X1A' 'T403X2A'  
'T403X3A' 'T403X4A' 'T402X1A' 'T402X2A' 'T402X3A' 'T402X4A' 'T404X1A' 'T404X2A' 
'T404X3A' 'T404X4A' 'T40601A' 'T40602A' 'T40603A' 'T40604A' 'T40691A' 'T40692A' 
'T40693A' 'T40694A' 
Opioid overdose '96500' '96502' '96509' 'E8501' 'E8502' 
Opioid use disorder  '30400' '30401' '30402' '30403' '30470' '30471' '30472' '30473' '30550' '30551' 
'30552' '30553' 
Tobacco  '3051' 'V1582' 
Alcohol  '3050' '3039' '2652' '3030' '3039' '3050' '3575' '4255' '5353' '980x' 'V113',  '2911' -
'2913', '2915' - '2919',  '5710' - '5713' 
Marijuana  '3043''3052' '3043' '30430' '30431'  '30432'  '30433' 
Cocaine '3056' '3042' '30420' '30421' '30422' '30423' 
Other substance use  '3053','3054','3057','3058','3059' 
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Appendix B. 
 
Table 1 List of medications classified as “other” under opioid  
medication types in Table 1,2 &3. 
Medications 
Acetaminophen with codeine 
Anhydrous morphine (Paregoric®) 
Brompheniramine, codeine with phenylephrine 
Butalbital, acetaminophen and caffeine with codeine phosphate  
Butalbital, aspirin, caffeine with codeine phosphate 
Carisoprodol, aspirin, and codeine phosphate 
Codeine sulfate 
Hydrocodone bitartrate with homatropine methylbromide  
Hydrocodone with chlorpheniramine  
 
 
 
 
 
Table 2. Use of Other Types of Insurance among 21,538 Patients Making Cash 
Payments for Opioid Prescriptions at Retail Pharmacies in R.I. in 2015 
 
Insurance types used Number of patients 
(%) 
Cash payment for all opioid dispensings 16,240 (75.40) 
Cash plus only one other type of insurance 4,835 (22.45) 
Cash plus 2 other types of insurance  447 (2.08) 
Cash plus 3 other types of insurance  16 (0.07) 
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Appendix C 
 
Table 1 Distribution of cash payment by opioid medication type among patients on  
chronic opioid therapy, Rhode Island Prescription Drug Monitoring Program, 2015  
Opioid medication type Overall 
N=472,737  
Cash payment 
N=38,220 (8.08)  
Insurance payment 
N=434,517 (91.92)  
Buprenorphine 
Butorphanol 
Fentanyl 
Hydrocodone 
Hydromorphone 
Levorphanol 
Meperidine 
Methadone 
Morphine 
Oxycodone 
Oxymorphone 
Pentazocine 
Tapentadol 
Tramadol 
Other 
Codeine-based 
  1,437 (0.30) 
     309 (0.07) 
12,992 (2.75) 
147,245 (31.15) 
  6,666 (1.41) 
         9 (0.00) 
       199 (0.04) 
  6,575 (1.39) 
24,999 (5.29) 
175,639 (37.15) 
  1,650 (0.35) 
     286 (0.06) 
     880 (0.19) 
74,843 (15.83) 
 3,554 (0.75) 
 15,454 (3.27) 
     90 (0.24) 
     10 (0.03) 
   922 (2.41) 
8,962 (23.45) 
   683 (1.79) 
       0 (0.00) 
     39 (0.10) 
   799 (2.09) 
1,634 (4.28) 
14,462 (37.84) 
       68 (0.18) 
     11 (0.03) 
     42 (0.11) 
9,069 (23.73) 
   542 (1.42) 
   887 (2.32) 
   1,347 (0.31) 
     299 (0.07) 
 12,070 (2.78) 
 138,283 (31.82) 
  5,983 (1.38) 
        9 (0.00) 
       160 (0.04) 
    5,776 (1.33) 
  23,365 (5.38) 
161,177 (37.09) 
  1,582 (0.36) 
    275 (0.06) 
   838 (0.19) 
65,774 (15.14) 
3,012 (0.69) 
 14,567 (3.35) 
 
 
 
Table 2 Listing of benzodiazepines dispensed at  
Rhode Island retail pharmacies, Rhode Island  
Prescription Drug Monitoring Program, 2015  
Type of benzodiazepine N (%) 
Clonazepam 
Alprazolam 
Lorazepam 
Diazepam 
Temazepam 
Triazolam 
Clorazepate 
Chlordiazepoxide 
Oxazepam 
clobazam 
Flurazepam 
Midazolam 
Estazolam 
186,727 (29.29) 
181,412 (28.46) 
163,083 (25.58) 
72,163 (11.32) 
22,875 (3.59) 
3,895 (0.61) 
3,259 (0.51) 
1,589 (0.25) 
929 (0.15) 
810 (0.13) 
561 (0.09) 
85 (0.01) 
83 (0.01) 
Total  637,471 
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Table 3 Characteristics of patients on COT by potential POM in RI PDMP, 2015  
Characteristic  Overall 
(N=45,332) 
No misuse  
(N= 35,317) 
Potential misuse 
(N= 10,015) 
Continuous variables, mean (SD) 
Number of Rx 
Average cost ($) 
Average total cost ($) 
Age (years) 
 
  10.43 (7.910 
  54.50 (138.18) 
868.19 (2955.84) 
  56.80 (16.29) 
 
    8.06 (5.33) 
  43.78 (119.10) 
507.99 (1839.21) 
  57.32 (16.64) 
 
    18.74 (9.65)* 
    92.32 (185.92) 
2138.41 (5054.64) 
    54.96 (14.82) 
Age group (years), N (%) 
< 44  
45-54  
55-64  
65+ 
 
  9,897 (21.83) 
  9,835 (21.70) 
11,822 (26.08) 
13,778 (30.39) 
 
  7,552 (21.38) 
  7,217 (20.43) 
  9,095 (25.75) 
11,453 (32.43) 
 
2,345 (23.41)* 
2,618 (26.14) 
2,727 (27.23) 
2,325 (23.22) 
Gender, N (%) 
Female 
Male 
 
26,799 (59.12) 
18,533 (40.88) 
 
20,903 (59.19) 
14,414 (40.81) 
 
5,896 (58.87) 
4,119 (41.13) 
Primary method of payment, N (%) 
Cash 
Medicaid  
Medicare  
Commercial Ins. 
Other 
 
  2,891 (6.38) 
  3,404 (7.51) 
15,635 (34.49) 
22,598 (49.85) 
     804 (1.77) 
 
   2,351 (6.66) 
   2,483 (7.03) 
12,336 (34.93) 
17,549 (49.69) 
     598 (1.69) 
 
   540 (5.39) 
   921 (9.20) 
3,299 (32.94) 
5,049 (50.41) 
   206 (2.06) 
Primary opioid type used, N (%) 
Hydrocodone  
Oxycodone  
Tramadol  
Other  
 
15,347 (33.85) 
15,577 (34.36) 
  8,795 (19.40) 
  5,613 (12.38) 
 
12,807 (36.26) 
10,647 (30.15) 
  7,634 (21.62) 
  4,229 (11.97) 
 
2,540 (25.36) 
4,930 (49.23) 
1,161 (11.59) 
1,384 (13.82) 
Number of opioid dispensing, N (%) 
≤ 5 
6-10 
11+ 
 
14,366 (31.69) 
10,894 (24.03) 
20,072 (44.28) 
 
14,253 (40.36) 
  9,570 (27.10) 
11,494 (32.55) 
 
   113 (1.13) 
1,324 (13.22) 
8,578 (85.65) 
Average daily MME, N (%) 
≤ 50 
50-90 
90+ 
 
35,370 (78.02) 
  6,482 (14.30) 
  3,480 (7.68) 
 
29,295 (82.95) 
  4,209 (11.92) 
  1,813 (5.13) 
 
6,075 (60.66) 
2,273 (22.70) 
1,667 (16.65) 
Number of opioid prescribers, N (%) 
1 
2 
3 
4+ 
 
13,021 (28.72) 
13,550 (29.89) 
  8,394 (18.52) 
10,367 (22.87) 
 
11,896 (33.68) 
12,585 (35.63) 
  6,700 (18.97) 
  4,136 (11.71) 
 
1,125 (11.23) 
   965 (9.64) 
1,694 (16.91) 
6,231 (62.22) 
Number of pharmacies visited, N (%) 
1 
2 
3 
4+ 
 
27,292 (60.20) 
12,024 (26.52) 
  3,846 (8.48) 
  2,170 (4.79) 
 
24,031 (68.04) 
  9,327 (26.41) 
  1,682 (4.76) 
     277 (0.78) 
 
3,261 (32.56) 
2,697 (26.93) 
2,164 (21.61) 
1,893 (18.90) 
Concurrent benzodiazepines, N (%) 
No 
Yes 
 
38,053 (83.94) 
  7,279 (16.06) 
 
30,691 (86.90) 
  4,626 (13.10) 
 
7,362 (73.51) 
2,653 (26.49) 
*All p-values were < 0.01 for bivariate analyses using X2 test to compare the difference in covariates 
between no misuse and potential opioid misuse.  
Abbreviations: COT=Chronic opioid therapy, PDMP=Prescription Drug Monitoring Program, Rx=prescription, 
MME=morphine milligram equivalent, SD=standard deviation. 
 
